Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | | |
|---|---|---|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | FEB 28 | PATDPAFULL - New display fields provide for legal status data from INPADOC |
| NEWS | 4 | FEB 28 | BABS - Current-awareness alerts (SDIs) available |
| NEWS | 5 | MAR 02 | GBFULL: New full-text patent database on STN |
| NEWS | 6 | MAR 03 | REGISTRY/ZREGISTRY - Sequence annotations enhanced |
| NEWS | 7 | MAR 03 | MEDLINE file segment of TOXCENTER reloaded |
| NEWS | 8 | MAR 22 | KOREAPAT now updated monthly; patent information enhanced |
| NEWS | 9 | MAR 22 | Original IDE display format returns to REGISTRY/ZREGISTRY |
| NEWS | 10 | MAR 22 | PATDPASPC - New patent database available |
| NEWS | 11 | MAR 22 | REGISTRY/ZREGISTRY enhanced with experimental property tags |
| NEWS | 12 | APR 04 | EPFULL enhanced with additional patent information and new fields |
| NEWS | 13 | APR 04 | EMBASE - Database reloaded and enhanced |
| NEWS | 14 | APR 18 | New CAS Information Use Policies available online |
| NEWS | 15 | APR 25 | Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications. |
| NEWS | 16 | APR 28 | Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus |
| NEWS | 17 | MAY 23 | GBFULL enhanced with patent drawing images |
| NEWS | 18 | MAY 23 | REGISTRY has been enhanced with source information from CHEMCATS |
| NEWS | 19 | JUN 06 | The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available |
| NEWS | 20 | JUN 13 | RUSSIAPAT: New full-text patent database on STN |
| NEWS | 21 | JUN 13 | FRFULL enhanced with patent drawing images |
| NEWS | 22 | JUN 27 | MARPAT displays enhanced with expanded G-group definitions and text labels |
| NEWS | 23 | JUL 01 | MEDICONF removed from STN |
| NEWS | 24 | JUL 07 | STN Patent Forums to be held in July 2005 |
| NEWS | 25 | JUL 13 | SCISEARCH reloaded |
| NEWS | 26 | JUL 20 | Powerful new interactive analysis and visualization software, STN AnaVist, now available |

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information

```
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:42:14 ON 09 AUG 2005

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:42:30 ON 09 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     8 AUG 2005  HIGHEST RN 859027-58-0
DICTIONARY FILE UPDATES:    8 AUG 2005  HIGHEST RN 859027-58-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
```

**********

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10698009.str




chain nodes :
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 33
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
2-28 4-21 7-33 8-11 9-20 11-12 12-13 13-14 13-29 14-15 15-16 15-30 16-17 17-18 17-19 19-31 21-22 22-23 22-26 23-24 23-27 24-25
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
2-28 4-21 13-29 15-30 17-18 17-19 21-22 22-26
exact bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 7-33 8-9 8-11 9-10 9-20 11-12 12-13 13-14 14-15 15-16 16-17 19-31 22-23 23-24 23-27 24-25
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 33:CLASS

Stereo Bonds:

11-8 (Single Wedge).
20-9 (Single Wedge).
27-23 (Single Wedge).
28-2 (Single Wedge).
29-13 (Single Wedge).
33-7 (Single Wedge).

Stereo Chiral Centers:

2 (Parity=Odd)
7 (Parity=Even)
8 (Parity=Odd)
9 (Parity=Odd)
13 (Parity=Odd)
23 (Parity=Odd)

Stereo RSS Sets:

Type=Relative (Default). 6 Nodes= 2 7 8 9 13 23

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> S L1
SAMPLE SEARCH INITIATED 11:42:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      7 TO ITERATE

100.0% PROCESSED         7 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            7 TO      298
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> S L1 SSS FULL
FULL SEARCH INITIATED 11:43:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    315 TO ITERATE

100.0% PROCESSED       315 ITERATIONS                             0 ANSWERS
SEARCH TIME: 00.00.01

L3             0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10698009a.str
```




```
chain nodes :
11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  32
ring nodes :
1  2  3  4  5  6  7  8  9  10
chain bonds :
2-28  4-21  7-32  8-11  9-20  11-12  12-13  13-14  13-29  14-15  15-16  15-30
16-17  17-18  17-19  21-22  22-23  22-26  23-24  23-27  24-25
```

ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
2-28 4-21 13-29 15-30 17-18 17-19 21-22 22-26
exact bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 7-32 8-9 8-11 9-10 9-20 11-12
12-13 13-14 14-15 15-16 16-17 22-23 23-24 23-27 24-25
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 32:CLASS

Stereo Bonds:

11-8 (Single Wedge).
20-9 (Single Wedge).
27-23 (Single Wedge).
28-2 (Single Wedge).
29-13 (Single Wedge).
32-7 (Single Wedge).

Stereo Chiral Centers:

2 (Parity=Odd)
7 (Parity=Even)
8 (Parity=Odd)
9 (Parity=Odd)
13 (Parity=Odd)
23 (Parity=Odd)

Stereo RSS Sets:

Type=Relative (Default). 6 Nodes= 2 7 8 9 13 23

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR




Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 11:44:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     24 TO ITERATE

100.0% PROCESSED       24 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          187 TO      773
PROJECTED ANSWERS:               0 TO        0

L5             0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 11:44:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    512 TO ITERATE

100.0% PROCESSED      512 ITERATIONS                               67 ANSWERS
SEARCH TIME: 00.00.01

L6             67 SEA SSS FUL L4

=> FIL HCAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
```

FULL ESTIMATED COST 323.52 323.73

FILE 'HCAPLUS' ENTERED AT 11:44:36 ON 09 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 9 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 8 Aug 2005 (20050808/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l6
L7 2139 L6

=> FIL CAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 2.45 326.18

FILE 'CAPLUS' ENTERED AT 11:44:56 ON 09 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 9 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 8 Aug 2005 (20050808/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 16

L8 2139 L6

=> FIL HCAPLUS
COST IN U.S. DOLLARS

| | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.45 | 326.63 |

FILE 'HCAPLUS' ENTERED AT 11:45:07 ON 09 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 9 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 8 Aug 2005 (20050808/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 11:42:14 ON 09 AUG 2005)

FILE 'REGISTRY' ENTERED AT 11:42:30 ON 09 AUG 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 67 S L4 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:44:36 ON 09 AUG 2005
L7 2139 S L6

FILE 'CAPLUS' ENTERED AT 11:44:56 ON 09 AUG 2005
L8 2139 S L6

FILE 'HCAPLUS' ENTERED AT 11:45:07 ON 09 AUG 2005

=> s l7 and composition
638314 COMPOSITION
288523 COMPOSITIONS
921226 COMPOSITION
(COMPOSITION OR COMPOSITIONS)
1351441 COMPN
544323 COMPNS
1655583 COMPN

```
                (COMPN OR COMPNS)
       2095452 COMPOSITION
                (COMPOSITION OR COMPN)
L9         327 L7 AND COMPOSITION

=> s l9 and sodium
        989801 SODIUM
            34 SODIUMS
        989810 SODIUM
                (SODIUM OR SODIUMS)
L10        132 L9 AND SODIUM

=> s l10 and pravastatin
          2420 PRAVASTATIN
             1 PRAVASTATINS
          2420 PRAVASTATIN
                (PRAVASTATIN OR PRAVASTATINS)
L11        127 L10 AND PRAVASTATIN

=> s l11 and hmg-coA
          9504 HMG
           101 HMGS
          9528 HMG
                (HMG OR HMGS)
         41216 COA
           918 COAS
         41395 COA
                (COA OR COAS)
          6052 HMG-COA
                (HMG(W)COA)
L12         52 L11 AND HMG-COA

=> s l12 and reductase
         82330 REDUCTASE
          6290 REDUCTASES
         83384 REDUCTASE
                (REDUCTASE OR REDUCTASES)
L13         51 L12 AND REDUCTASE

=> s l13 and inhibitor
        480825 INHIBITOR
        494689 INHIBITORS
        766615 INHIBITOR
                (INHIBITOR OR INHIBITORS)
L14         51 L13 AND INHIBITOR

=> s l14 and purified
        407513 PURIFIED
             2 PURIFIEDS
        407515 PURIFIED
                (PURIFIED OR PURIFIEDS)
L15          0 L14 AND PURIFIED

=> s l14 and impurity
        154887 IMPURITY
        191116 IMPURITIES
        285990 IMPURITY
                (IMPURITY OR IMPURITIES)
L16          0 L14 AND IMPURITY
```

```
=> s l14 and py<=1998
      18939279 PY<=1998
L17           6 L14 AND PY<=1998

=> s 14 and p/dt
   REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.



SAMPLE SEARCH INITIATED 11:51:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      24 TO ITERATE

100.0% PROCESSED       24 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          187 TO      773
PROJECTED ANSWERS:               0 TO        0

L18            0 SEA SSS SAM L4



L19            0 L18


       4780857 P/DT
L20            0 L19 AND P/DT

=> d his

     (FILE 'HOME' ENTERED AT 11:42:14 ON 09 AUG 2005)

     FILE 'REGISTRY' ENTERED AT 11:42:30 ON 09 AUG 2005
L1               STRUCTURE UPLOADED
L2             0 S L1
L3             0 S L1 SSS FULL
L4               STRUCTURE UPLOADED
L5             0 S L4
L6            67 S L4 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 11:44:36 ON 09 AUG 2005
L7          2139 S L6

     FILE 'CAPLUS' ENTERED AT 11:44:56 ON 09 AUG 2005
L8          2139 S L6

     FILE 'HCAPLUS' ENTERED AT 11:45:07 ON 09 AUG 2005
L9           327 S L7 AND COMPOSITION
L10          132 S L9 AND SODIUM
L11          127 S L10 AND PRAVASTATIN
L12           52 S L11 AND HMG-COA
L13           51 S L12 AND REDUCTASE
```

```
L14           51 S L13 AND INHIBITOR
L15            0 S L14 AND PURIFIED
L16            0 S L14 AND IMPURITY
L17            6 S L14 AND PY<=1998
               S L4 AND P/DT

     FILE 'REGISTRY' ENTERED AT 11:51:36 ON 09 AUG 2005
L18            0 S L4

     FILE 'HCAPLUS' ENTERED AT 11:51:37 ON 09 AUG 2005
L19            0 S L18
L20            0 S L19 AND P/DT

=> s l14 and pc/us
'US' IS NOT A VALID FIELD CODE
             0 PC/US
L21          0 L14 AND PC/US

=> s l14 and us/pc
       1394437 US/PC
L22         32 L14 AND US/PC

=> d l17 ibib abs hitstr tot

L17 ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         1998:98321  HCAPLUS
DOCUMENT NUMBER:          128:196661
TITLE:                    Antithrombotic and antiatherogenic pharmaceutical
                          composition including a thienopyridine
                          derivative and an HMG-CoA
                          reductase inhibitor
INVENTOR(S):              Daste, Georges; Herbert, Jean-Marc
PATENT ASSIGNEE(S):       Sanofi, Fr.
SOURCE:                   PCT Int. Appl., 30 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
     WO 9804259            A1    19980205    WO 1997-FR1353         19970721 <--
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,
             UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
             GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
             GN, ML, MR, NE, SN, TD, TG
     FR 2751540            A1    19980130    FR 1996-9474           19960726 <--
     FR 2751540            B1    19981016
     ZA 9706247            A     19990115    ZA 1997-6247           19970715
     CA 2261099            AA    19980205    CA 1997-2261099        19970721 <--
     CA 2261099            C     20030415
     AU 9738526            A1    19980220    AU 1997-38526          19970721 <--
     AU 725949             B2    20001026
     EP 914124             A1    19990512    EP 1997-935593         19970721
```

| | | | | | |
|---|---|---|---|---|---|
| EP 914124 | B1 | 20040121 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | | |
| BR 9710560 | A | 19990817 | BR 1997-10560 | | 19970721 |
| CN 1228698 | A | 19990915 | CN 1997-197539 | | 19970721 |
| CN 1109547 | B | 20030528 | | | |
| JP 2000500781 | T2 | 20000125 | JP 1998-508545 | | 19970721 |
| JP 3553610 | B2 | 20040811 | | | |
| NZ 333826 | A | 20000929 | NZ 1997-333826 | | 19970721 |
| RU 2176504 | C2 | 20011210 | RU 1999-103623 | | 19970721 |
| EE 3853 | B1 | 20021015 | EE 1999-28 | | 19970721 |
| AT 258052 | E | 20040215 | AT 1997-935593 | | 19970721 |
| PT 914124 | T | 20040531 | PT 1997-935593 | | 19970721 |
| ES 2214632 | T3 | 20040916 | ES 1997-935593 | | 19970721 |
| CZ 294664 | B6 | 20050216 | CZ 1999-176 | | 19970721 |
| PL 188739 | B1 | 20050429 | PL 1997-331339 | | 19970721 |
| KR 2000029484 | A | 20000525 | KR 1999-700501 | | 19990122 |
| US 6218403 | B1 | 20010417 | US 1999-230299 | | 19990122 |
| NO 9900321 | A | 19990322 | NO 1999-321 | | 19990125 |
| HK 1019405 | A1 | 20031017 | HK 1999-104578 | | 19991101 |
| PRIORITY APPLN. INFO.: | | | FR 1996-9474 | A | 19960726 |
| | | | WO 1997-FR1353 | W | 19970721 |

OTHER SOURCE(S): MARPAT 128:196661

GI




I

AB A pharmaceutical **composition** containing (a) a thienopyridine derivative (I; R = H, C1-4 alkoxycarbonyl) or a pharmaceutically acceptable salt thereof; and (b) an **HMG-CoA-reductase inhibitor**, is disclosed. A combination of 5 mg/kg clopidogrel and 5 mg/kg simavastatin had synergistic effect and inhibited the formation of thrombose by 72% in rabbits. A 2-layered pharmaceutical tablet contained ticlopidine hydrochloride 200.00, microcryst. cellulose 69.88, maize starch 31.20, polyvidone 6.24, citric acid 3.12, stearic acid 0.78, magnesium stearate 0.78 mg in the first layer and simavastatin 20.00, butydroyxanisole 0.04, ascorbic acid 5.00, citric acid 2.50, microcryst. cellulose 10.00, maize starch 20.00, lactose 141.50, magnesium stearate 1.00, methylhydroy Pr cellulose 1.65, hydroxypropyl cellulose 1.65, titanium dioxide 1.50, talc 0.60, yellow ferric oxide 0.092, and red ferric oxide 0.023 mg in the second layer.

IT **81131-70-6, Pravastatin Sodium**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antithrombotic and antiatherogenic pharmaceutical **composition** including thienopyridine derivative and **HMG-CoA reductase inhibitor**)

RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:315691 HCAPLUS
DOCUMENT NUMBER: 126:334419
TITLE: Pharmaceutical **compositions** for preventing a second heart attack containing an **HMG CoA reductase inhibitor**
INVENTOR(S): Olukotun, Adeove Y.; Alexander, John C.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 8 pp., Cont.-in-part of U.S. Ser. No. 824,679, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|---|---|---|---|---|---|
| US 5622985 | A | 19970422 | US 1995-424984 | 19950419 | <-- |
| CA 2172884 | AA | 19961020 | CA 1996-2172884 | 19960328 | <-- |
| EP 738512 | A1 | 19961023 | EP 1996-106104 | 19960418 | <-- |
| EP 738512 | B1 | 20030702 | | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | | |
| AU 9650741 | A1 | 19961031 | AU 1996-50741 | 19960418 | <-- |
| AU 715181 | B2 | 20000120 | | | |
| AT 244006 | E | 20030715 | AT 1996-106104 | 19960418 | |
| PT 738512 | T | 20031128 | PT 1996-106104 | 19960418 | |
| ES 2202393 | T3 | 20040401 | ES 1996-106104 | 19960418 | |
| JP 08291082 | A2 | 19961105 | JP 1996-98084 | 19960419 | <-- |
| PRIORITY APPLN. INFO.: | | | US 1990-536367 | B1 19900611 | |
| | | | US 1992-824679 | B2 19920123 | |
| | | | US 1995-424984 | A 19950419 | |

AB A pharmaceutical **compns.** is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an **HMG CoA reductase inhibitor** such as **pravastatin** (I), alone or in combination with an ACE **inhibitor.** A tablet contained I 7, lactose 67, microcryst. cellulose 20, croscarmellose **sodium** 2, magnesium stearate 2, and magnesium oxide 3 parts.

IT **81093-37-0, Pravastatin**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical **compns.** for preventing second heart attack containing **HMG CoA reductase inhibitor**)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:192587 HCAPLUS
DOCUMENT NUMBER: 126:258927
TITLE: Effects of low-dose **pravastatin sodium** on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year
AUTHOR(S): Harsch, Michael; Braesen, Jan Hinrich; Niendorf, Axel
CORPORATE SOURCE: Institute Pathology, University Hamburg, Hamburg, 20246, Germany
SOURCE: Atherosclerosis (Shannon, Ireland) (**1997**), 128(2), 139-147
CODEN: ATHSBL; ISSN: 0021-9150
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The aim of this study was to evaluate the cholesterol-lowering and antiatherosclerotic effect of the **HMG-CoA reductase inhibitor pravastatin sodium** at a dosage comparable to human therapy. Twelve heterozygous WHHL rabbits (13 mo old) were fed 100 g per day of a low cholesterol (0.03%) enriched diet for 12 mo. Six of these animals also received **pravastatin sodium** at a daily dose of 1 mg/kg body weight (verum group). In the verum group, total plasma cholesterol levels were lower by 47% ($P < 0.05$)

and relative aortic plaque volume (% ratio of total plaque volume to the aortic lumen) was reduced by 78% ($P < 0.05$), when compared to the control group. Plaque **composition** was analyzed at 30 cross-sectional levels of the entire aortic wall using a grid window. Compared to the control group, the plaque type, in terms of architecture and **composition**, was altered as follows: lesions in the verum group had no confluent atheromatous cores and showed a pattern of a diffuse mixture of the main plaque components with a decreased relative content of necrosis (-44%) and an increased relative content of smooth muscle cells (+19%), whereas the relative content of macrophage-derived foam cells and collagen were nearly unaffected. Furthermore, a similar plaque volume and type was observed in animals with comparable cholesterol profiles. There was no histol. evidence for structurally damaging effects of **pravastatin sodium** on the arterial wall. We conclude that **pravastatin sodium** reduces total plasma cholesterol levels in this animal model, thereby leading to smaller plaques and a different plaque type.

IT **81093-37-0, Pravastatin**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(effects of low-dose **pravastatin sodium** on plasma cholesterol levels and aortic atherosclerosis in heterozygous WHHL rabbits fed low cholesterol diet)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:178769 HCAPLUS

DOCUMENT NUMBER: 126:176899

TITLE: Synergistic combination comprising an insulin sensitizer and a **HMG-CoA reductase inhibitor** for treating arteriosclerosis

INVENTOR(S): Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 753298 | A1 | 19970115 | EP 1996-304924 | 19960703 <-- |
| EP 753298 | B1 | 20011121 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| CA 2180296 | AA | 19970104 | CA 1996-2180296 | 19960702 <-- |
| NO 9602784 | A | 19970106 | NO 1996-2784 | 19960702 <-- |
| AU 9656261 | A1 | 19970116 | AU 1996-56261 | 19960702 <-- |
| AU 706628 | B2 | 19990617 | | |
| JP 09071540 | A2 | 19970318 | JP 1996-172137 | 19960702 <-- |
| JP 3651816 | B2 | 20050525 | | |
| US 5798375 | A | 19980825 | US 1996-676090 | 19960702 <-- |
| IL 118778 | A1 | 19990714 | IL 1996-118778 | 19960702 |
| RU 2158607 | C2 | 20001110 | RU 1996-112769 | 19960702 |
| TW 474809 | B | 20020201 | TW 1996-85107984 | 19960702 |
| ZA 9605650 | A | 19970127 | ZA 1996-5650 | 19960703 <-- |
| CN 1148492 | A | 19970430 | CN 1996-112170 | 19960703 <-- |
| CN 1089584 | B | 20020828 | | |
| CZ 286832 | B6 | 20000712 | CZ 1996-1982 | 19960703 |
| AT 209046 | E | 20011215 | AT 1996-304924 | 19960703 |
| ES 2165474 | T3 | 20020316 | ES 1996-304924 | 19960703 |
| PT 753298 | T | 20020328 | PT 1996-304924 | 19960703 |
| US 6159997 | A | 20001212 | US 1998-61446 | 19980416 |
| HK 1011928 | A1 | 20020628 | HK 1998-113080 | 19981210 |
| JP 2004075691 | A2 | 20040311 | JP 2003-359698 | 20031020 |
| JP 2004250455 | A2 | 20040909 | JP 2004-96229 | 20040329 |
| PRIORITY APPLN. INFO.: | | | JP 1995-167291 A | 19950703 |
| | | | JP 1996-172137 A3 | 19960702 |
| | | | US 1996-676090 A3 | 19960702 |

AB A combination of 1 or more HMG-CoAreductase **inhibitors** (e.g., **pravastatin**, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with 1 or more insulin sensitizers (e.g., troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]ethoxy)benzyl}thiazolidine-2,4-dione) exhibits a synergistic effect and is better at prevention and/or treatment of arteriosclerosis and/or xanthoma than is either of the components of the combination alone. Thus, **pravastatin sodium** 0.5, troglitazone 20, Crospovidone 1.5, and Na lauryl sulfate 0.2 g were blended and the mixture was divided among 100 capsules, each containing 5 mg **pravastatin sodium** and 200 mg troglitazone. The preparation of some thiazolidine-2,4-diones is reported.

IT **81093-37-0**, **Pravastatin 81131-70-6**, **Pravastatin sodium**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic **composition** containing insulin sensitizer and **HMG -CoA reductase inhibitor** for treatment of arteriosclerosis)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L17 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:701531 HCAPLUS
DOCUMENT NUMBER: 125:339030
TITLE: Use of **HMG CoA reductase inhibitor** to prevent second heart attack
INVENTOR(S): Olukotun, Adeoye Y.; Alexander, John C.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 738512 | A1 | 19961023 | EP 1996-106104 | 19960418 <-- |
| EP 738512 | B1 | 20030702 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| US 5622985 | A | 19970422 | US 1995-424984 | 19950419 <-- |
| PRIORITY APPLN. INFO.: | | | US 1995-424984 A | 19950419 |

US 1990-536367 B1 19900611
US 1992-824679 B2 19920123

AB A method is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an **HMG CoA reductase inhibitor** such as **pravastatin**, alone or in combination with an ACE **inhibitor.** Tablets were formulated containing **pravastatin** 7, lactose 67, microcryst. cellulose 20, croscarmellose **sodium** 2, magnesium stearate 1, and magnesium oxide 3 parts by weight

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**HMG CoA reductase inhibitor** to prevent second heart attack and pharmaceutical **compns.** containing **HMG CoA reductase inhibitor** and other ingredients)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:497325 HCAPLUS
DOCUMENT NUMBER: 125:151167
TITLE: A controlled release drug delivery device comprising two-layered core and coating
INVENTOR(S): Rork, Gerald S.; Pipkin, James D.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9619201 | A1 | 19960627 | WO 1995-US16530 | 19951218 <-- |

W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| US 5582838 | A | 19961210 | US 1994-363451 | 19941222 | <-- |
| CA 2206211 | AA | 19960627 | CA 1995-2206211 | 19951218 | <-- |
| AU 9644726 | A1 | 19960710 | AU 1996-44726 | 19951218 | <-- |
| AU 693313 | B2 | 19980625 | | | |
| EP 801560 | A1 | 19971022 | EP 1995-943469 | 19951218 | <-- |
| EP 801560 | B1 | 20030702 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE | | | | | |
| CN 1171048 | A | 19980121 | CN 1995-196988 | 19951218 | <-- |
| CN 1081916 | B | 20020403 | | | |
| HU 77370 | A2 | 19980330 | HU 1997-1914 | 19951218 | <-- |
| JP 11509829 | T2 | 19990831 | JP 1995-519938 | 19951218 | |
| SK 281224 | B6 | 20010118 | SK 1997-805 | 19951218 | |
| RU 2168330 | C2 | 20010610 | RU 1997-112378 | 19951218 | |
| PL 183615 | B1 | 20020628 | PL 1995-320792 | 19951218 | |
| CZ 290802 | B6 | 20021016 | CZ 1997-1895 | 19951218 | |
| AT 244001 | E | 20030715 | AT 1995-943469 | 19951218 | |
| PT 801560 | T | 20031031 | PT 1995-943469 | 19951218 | |
| ES 2201133 | T3 | 20040316 | ES 1995-943469 | 19951218 | |
| FI 9702586 | A | 19970617 | FI 1997-2586 | 19970617 | <-- |
| NO 9702880 | A | 19970620 | NO 1997-2880 | 19970620 | <-- |
| PRIORITY APPLN. INFO.: | | | US 1994-363451 A | 19941222 | |
| | | | WO 1995-US16530 W | 19951218 | |

AB A device disclosed for the controlled delivery of a beneficial agent consisting of (1) a core comprising at least two layers, wherein at least one layer comprises a beneficial agent and a polymer which forms microscopic gel beads upon hydration and at least one layer which comprises a polymer which forms microscopic gel beads upon hydration; and (2) an impermeable, insol. coating which adheres to and surrounds the core and contains apertures which provide an area for the hydration and release of the microscopic gel beads. A two-layered core contained lovastatin (I) 40, Carbopol 974P 16, trisodium citrate 32, and lactose 16 mg/layer in the first layer and Avicel PH101 20, Carbopol 974P 8, trisodium citrate 16, and lactose 8 mg/layer in the second layer. The cores were coated with a solution of cellulose acetate butyrate 20, and triethylcitrate 3 parts in a solution of acetone:ethanol (3:1) and sprayed onto the cores to a thickness of 100μm and two holes were drilled in the face of the device. The release profile of the two layer device were significantly improved over the single **composition** core, in that the last 20% of I was released at a more constant rate and greater than 95% of the I content was released in <20 h.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled release drug delivery device comprising two-layered core and coating)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d 122 ibib abs hitstr tot

L22 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:411059 HCAPLUS
DOCUMENT NUMBER: 142:469260
TITLE: HDL-boosting combination therapy complexes
INVENTOR(S): Tunac, Josefino B.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2005101561 | A1 | 20050512 | US 2004-983836 | 20041108 <-- |
| WO 2005046662 | A2 | 20050526 | WO 2004-US37324 | 20041108 |
| WO 2005046662 | A3 | 20050623 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-518091P P 20031107

AB A pharmaceutical **composition** including therapeutically effective amts. of at least one **HMG-CoA reductase inhibitor** present as a dyhydroxyacid salt and at least one addnl. therapeutic agent is claimed. Dehydroxy acid salt of **sodium** lovastatin (I) was prepared and its antilipidemic activity was studied in hamster. A repeat side-by-side comparison between I and Lipitor at 5-20 mg dose range confirmed the effectiveness of I in decreasing LDL, moreover, I was effective at a dose as low as 5 mg.

IT **81093-37-0, Pravastatin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HDL-boosting combination therapy complexes)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L22 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:346827 HCAPLUS
DOCUMENT NUMBER: 142:397743
TITLE: A solid dosage form comprising a fibrate and a statin
INVENTOR(S): Holm, Per; Norling, Tomas
PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005034908 | A2 | 20050421 | WO 2004-DK668 | 20041001 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2005096390 | A1 | 20050505 | US 2004-988818 | 20041115 <-- |
| US 2005096391 | A1 | 20050505 | US 2004-988829 | 20041115 <-- |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| DK 2003-1503 | A | 20031010 |
| DK 2004-464 | A | 20040323 |
| WO 2004-DK668 | A2 | 20041001 |

AB The present invention relates to pharmaceutical **compns.** in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a **HMG CoA reductase inhibitors**). The **compns** . are manufactured without any need of addition of water or an aqueous medium and wherein at least 80% of the active substances (i.e., the fibrate and the

statin) are present in the **composition** in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration. Thus, tablets contained fenofibrate 160.09, PEG 208.12, Poloxamer-188 89.19, lactose 356.51, and Mg stearate 4.09 mg.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid dosage form comprising fibrate and statin)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L22 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:995960 HCAPLUS
DOCUMENT NUMBER: 141:416027
TITLE: Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a **HMG CoA reductase inhibitor**
INVENTOR(S): Urata, Yasuo; Hoshino, Shoji; Kawamura, Hitoshi; Okamoto, Hiroshi; Furukawa, Noboru
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004098583 | A1 | 20041118 | WO 2004-US13633 | 20040430 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2005020668 | A1 | 20050127 | US 2004-835916 | 20040430 <-- |

PRIORITY APPLN. INFO.: US 2003-467418P P 20030502
US 2003-471495P P 20030516
US 2003-477372P P 20030610
US 2004-534856P P 20040108

AB The invention provides a combination comprising (a) S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate (I) or prodrug of the active form thereof, and (b) at least one **HMG CoA reductase inhibitor.** Also provided are a pharmaceutical **composition**, package, and a kit comprising the the active ingredients, as well as a method for treatment and prophylaxis of a cardiovascular disorder involving the use of the the active ingredients. Thus, the combination of I and a **HMG CoA reductase inhibitor** decreased the atherogenic index in rabbits on a high cholesterol diet.

IT **81093-37-0, Pravastatin 81131-70-6, Pravastatin sodium 791595-03-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination comprising (ethylbutyl)cyclohexylcarbonylaminophenyl methylpropanethioate and **HMG CoA reductase inhibitor**)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791595-03-4 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)-, mixt. with S-[2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl] 2-methylpropanethioate (9CI) (CA INDEX NAME)

CM 1

CRN 211513-37-0
CMF C23 H35 N O2 S



CM 2

CRN 81131-70-6
CMF C23 H36 O7 . Na

Absolute stereochemistry.



● Na

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:589248 HCAPLUS
DOCUMENT NUMBER: 141:140474
TITLE: Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
INVENTOR(S): Sher, Philip M.; Ellsworth, Bruce A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 43 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| US 2004142938 | A1 | 20040722 | US 2003-712823 | | 20031113 <-- |
| PRIORITY APPLN. INFO.: | | | US 2002-426465P | P | 20021114 |

OTHER SOURCE(S): MARPAT 141:140474
GI



I



= W1



= W2



= W3

AB Prodrugs of glycogen phosphorylase inhibiting compds. are provided, said prodrug compds., G(-O2CR')m(-OH)n(-O2C(CH2)pCH3)q [G = branched or straight C3-5-carbon chain and (-O2CR'), (-OH) and (-O2C(CH2)pCH3) are attached to any available carbon atom along G; m = 1 - 4; n = 0 - 3; p = 0 - 16; q = 0 - 3; where m + n + q = 3 or 4; and -O2CR' is a fragment of a compound I wherein W = W1, W2, W3; X = O, S, SO2, CHR5, , CHR5O, CHR5S, CHR5SO2, CHR5CO, CH2CHR5; Y = bond, CHR6; Z = aryl, heteroaryl; R1 =H, alkyl, alkenyl; R2 = H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkenyl; R3, R4 = H, halo, CF3, CN, alkyl, alkoxy; R5, R6 = H, alkyl, aryl, alkenyl, CN, CN4R9A (tetrazole), CO2R9A, CONR9AR9B, CONR9AOR9B; A = CH, N; B = O, S; wherein R1, R2, R5, R6, R7, R8 = alkyl, aryl, alkenyl, arylalkyl,heteroarylalkyl, alkoxy, aryloxy and each may be substituted with 1 - 3 hydrogen bonding groups]. Thus, 3-[(5-chloroindolecarbonyl)amino]-3,4-dihydrocarbostyril I (R1 = R2 = H, W = 5-chloroindole, X = CH2, YZ = benzo) was prepared from 3-amino-3,4-dihydrocarbostyril via acylation with 5-chloroindolecarboxylic acid resin-bound 2,3,5,6-tetrafluorophenyl ester. Further provided are pharmaceutical **compns.** and methods for treating diabetes and related diseases employing compds. above, either alone or in combination with another therapeutic agent.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(companion therapeutic agent (lipid-lowering); preparation of triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compds.)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 5 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:550886 HCAPLUS
DOCUMENT NUMBER: 141:94364
TITLE: **Compositions** of cholesteryl ester transfer protein **inhibitors** and **HMG-COA reductase inhibitors**
INVENTOR(S): Babcock, Walter Christian; Friesen, Dwayne Thomas; Smithey, Daniel Tod; Shanker, Ravi Mysore
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004056395 | A1 | 20040708 | WO 2003-IB6170 | 20031218 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004132771 | A1 | 20040708 | US 2003-678145 | 20031006 <-- |
| WO 2004056396 | A1 | 20040708 | WO 2003-IB6240 | 20031218 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRIORITY APPLN. INFO.: US 2002-435328P P 20021220

AB A **composition** comprises (1) a solid amorphous adsorbate comprising a cholesteryl ester transfer protein (CETP) **inhibitor** and a substrate; and (2) an **HMG-CoA reductase**

**inhibitor** is disclosed. The solid amorphous adsorbate provides concentration enhancement of the CETP **inhibitor** relative to a control **composition** consisting essentially of the unadsorbed CETP **inhibitor** alone, resulting in improved bioavailability. A solid amorphous adsorbate was prepared from torcetrapib, fumed silica (Cab-O-Sil), and mixed with granules containing atorvastatin hemicalcium trihydrate, calcium carbonate, microcryst. cellulose, croscarmellose **sodium**, polysorbate, hydroxypropyl cellulose, and pregelatinized starch, and then pressed into 150 mg compacts. The resulting compacts each contained 32 mg torcetrapib and 3.2 mg atorvastatin trihydrate hemicalcium salt.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**compns.** of cholesteryl ester transfer protein **inhibitors** and **HMG-COA reductase inhibitors**)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 6 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:100987 HCAPLUS
DOCUMENT NUMBER: 140:151978
TITLE: **Composition** comprising a cholesterol absorption **inhibitor**, an **HMG-CoA reductase inhibitor** and a stabilizing agent
INVENTOR(S): Moore, William D.; Fitzpatrick, Shaun; Seiler, Christian; Saklatvala, Robert; Petts, Catherine R.; Cho, Wing-Kee Philip
PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK; Schering Corporation
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004010993 | A1 | 20040205 | WO 2003-US22889 | 20030722 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| CA 2493076 | AA | 20040205 | CA 2003-2493076 | | 20030722 |
| US 2004126423 | A1 | 20040701 | US 2003-625004 | | 20030722 <-- |
| EP 1531805 | A1 | 20050525 | EP 2003-771709 | | 20030722 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | | |
| BR 2003012933 | A | 20050712 | BR 2003-12933 | | 20030722 |
| PRIORITY APPLN. INFO.: | | | US 2002-398691P | P | 20020726 |
| | | | WO 2003-US22889 | W | 20030722 |

AB The instant invention provides a pharmaceutical **composition** comprised of a cholesterol absorption **inhibitor** and an **HMG-CoA reductase inhibitor**, one or more anti-oxidants, microcryst. cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The **composition** need not contain ascorbic acid in order to obtain desirable stability. Tablets were prepared containing ezetimibe, simvastatin and BHA.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals comprising a cholesterol absorption **inhibitor**, an **HMG-CoA reductase inhibitor** and a stabilizing agent)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 7 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:1007596 HCAPLUS
DOCUMENT NUMBER: 140:65183
TITLE: Oil-containing, orally administrable pharmaceutical **composition** for improved delivery of a therapeutic agent
INVENTOR(S): Chen, Feng-Jing; Patel, Mahesh V.
PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Pat. Appl. 2002.32,171.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003235595 | A1 | 20031225 | US 2003-397969 | 20030325 <-- |
| US 6267985 | B1 | 20010731 | US 1999-345615 | 19990630 <-- |
| US 6309663 | B1 | 20011030 | US 1999-375636 | 19990817 <-- |
| US 2001024658 | A1 | 20010927 | US 2000-751968 | 20001229 <-- |
| US 6458383 | B2 | 20021001 | | |
| US 2002032171 | A1 | 20020314 | US 2001-877541 | 20010608 <-- |
| US 6761903 | B2 | 20040713 | | |
| WO 2004087052 | A2 | 20041014 | WO 2004-US9120 | 20040325 |
| WO 2004087052 | A3 | 20041118 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 1999-345615 | A2 | 19990630 |
| US 1999-375636 | A2 | 19990817 |
| US 2000-751968 | A2 | 20001229 |
| US 2001-877541 | A2 | 20010608 |
| WO 2000-US18807 | A | 20000710 |
| US 2003-397969 | A | 20030325 |


AB The present invention relates to oral pharmaceutical **compns.** and methods for improved delivery of therapeutic agents, e.g., lipid-regulating agents. **Compns.** of the present invention include a carrier, where the carrier contains a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the **composition** forms a clear, aqueous dispersion. The invention also pertains to methods for treating lipid disorders such as hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia by oral administration of the **compns.** provided.

IT **81093-37-0, Pravastatin**
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oral **composition** containing triglyceride and surfactants for improved delivery of hydrophobic drugs)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 8 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:777602 HCAPLUS
DOCUMENT NUMBER: 139:296975
TITLE: Combination of a **HMG-CoA reductase inhibitor** and an insulin secretion enhancer
INVENTOR(S): Damon, Robert Edson; Hughes, Thomas Edward; Burkey, Bryan
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003080070 | A2 | 20031002 | WO 2003-EP2978 | 20030321 |
| WO 2003080070 | A3 | 20040325 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW | | | | |
| RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR | | | | |
| CA 2479880 | AA | 20031002 | CA 2003-2479880 | 20030321 |
| US 2004002519 | A1 | 20040101 | US 2003-393798 | 20030321 <-- |
| EP 1523316 | A2 | 20050420 | EP 2003-744834 | 20030321 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003008613 | A | 20050301 | BR 2003-8613 | 20030324 |

| PRIORITY APPLN. INFO.: | | | |
|---|---|---|---|
| US 2002-366752P | P | 20020322 | |
| WO 2003-EP2978 | W | 20030321 | |

AB The present invention relates to a combination pharmaceutical **composition** comprising as active ingredients (i) a **HMG-CoA reductase inhibitor** or a salt, (ii) (a) an insulin secretion enhancer or a salt or (b) an insulin sensitizer or a salt. Thus, capsules contained fluvastatin **sodium** 42.962, CaCO3 125.680, NaHCO3 4.000, microcryst. cellulose 114.440, pregelatinized starch 83.800, Mg stearate 21.00, and talc 18.860 mg, and water qs.
IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of **HMG-CoA reductase**

**inhibitor** and insulin secretion enhancer)
RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L22 ANSWER 9 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:717761 HCAPLUS
DOCUMENT NUMBER: 139:235434
TITLE: **Compositions** containing insulin-secretion stimulant and a **HMG-CoA reductase inhibitor** for reducing blood glucose and cholesterol
INVENTOR(S): Freese, Lori M.; Gorham, Thomas R.; Wheeler-Davis, Jennifer A.
PATENT ASSIGNEE(S): Upsher-Smith Laboratories, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003171407 | A1 | 20030911 | US 2002-94004 | 20020307 <-- |
| WO 2003075933 | A1 | 20030918 | WO 2003-US6937 | 20030306 |

W: CA
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: US 2002-94004 A 20020307

AB The invention provides a pharmaceutical **composition** which is a combination of an insulin-secretion stimulant and a **HMG-CoA reductase inhibitor.** Suitable insulin-secretion stimulants include the sulfonylurea drugs, and suitable **HMG-CoA reductase inhibitors** include the statin drugs. The **composition** may be formulated to provide extended-release characteristics of 1 or both of the active components. Also provided are methods for treating a diabetic patient by using a combination of an insulin-secretion stimulant and a **HMG-CoA reductase inhibitor.** Practice of the methods of the invention may result in the administration of fewer dosages to the patient. The invention also provides a pharmaceutical **composition** which is a combination of an antihyperglycemic drug,

particularly a biguanide compound, in combination with a **HMG-CoA reductase inhibitor.** Also provided are methods for treating a diabetic patient using a combination of an antihyperglycemic biguanide compound and a **HMG-CoA reductase inhibitor.**

IT **81131-70-6, Pravastatin sodium**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**compns.** containing insulin-secretion stimulant and **HMG-CoA reductase inhibitor** for reducing blood glucose and cholesterol)

RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L22 ANSWER 10 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:492702 HCAPLUS
DOCUMENT NUMBER: 139:47580
TITLE: Combinations of hormone replacement therapy **composition**(s) and sterol absorption **inhibitor**(s) and treatments for vascular conditions in post-menopausal women
INVENTOR(S): Strony, John T.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 166,942.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| US 2003119796 | A1 | 20030626 | US 2002-247085 | | 20020919 <-- |
| US 2003105028 | A1 | 20030605 | US 2002-166942 | | 20020611 <-- |
| PRIORITY APPLN. INFO.: | | | US 2001-324118P | P | 20010921 |
| | | | US 2002-166942 | A2 | 20020611 |
| | | | US 2000-256875P | P | 20001220 |
| | | | US 2001-23295 | A2 | 20011217 |

OTHER SOURCE(S): MARPAT 139:47580

AB The present invention provides **compns.**, therapeutic combinations and methods including: (a) at least one hormone replacement therapy **composition**; and (b) at least one sterol absorption **inhibitor** which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5α-stanols.

IT **81093-37-0, Pravastatin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of hormone replacement therapy **composition**(s) and sterol absorption **inhibitor**(s) and treatments for vascular conditions in post-menopausal women)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 11 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:455033 HCAPLUS

DOCUMENT NUMBER: 139:41802

TITLE: Stabilized pharmaceuticals containing **HMG-CoA reductase inhibitors**

INVENTOR(S): Pflaum, Zlatko; Kerc, Janez

PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia

SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U. S. Ser. No. 591,322.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003109584 | A1 | 20030612 | US 2002-298187 | 20021115 <-- |
| US 6806290 | B2 | 20041019 | | |
| US 6531507 | B1 | 20030311 | US 2000-591322 | 20000609 <-- |
| ES 2215050 | T3 | 20041001 | ES 2000-931486 | 20000609 |
| PRIORITY APPLN. INFO.: | | | US 2000-591322 A2 | 20000609 |
| | | | EP 2000-931486 A | 20000609 |

AB Lovastatin, **pravastatin**, simvastatin, mevastatin, atorvastatin, and derivs. and analogs thereof are known as **HMG-CoA reductase inhibitors** and are used as antihypercholesterolemic agents. The majority of them are produced by

fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a **HMG-CoA reductase inhibitor** which is stabilized by forming a homogeneous **composition** with a buffering substance or a basifying substance. This homogeneous **composition** is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. **Pravastatin Sodium** (5 g) with chromatog. purity 99.5% and pH 7.4 (1%)/7.7 (5%) was dissolved in MeOH (30 mL), and Na2CO3 (10 mg, dissolved in 0.15 mL of water) was added and finally, EtOAc (400 mL containing 2% of water) was added. Fter 1 h the resulted crystals were filtered off, washed with fresh EtOAc (50 mL) and dried at 40° for 6 h in vacuo. The chromatog. purity of resulting crystals (4.3 g) was 99.6%.

IT **81093-37-0, Pravastatin 81131-70-6, Pravastatin sodium**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized pharmaceuticals containing **HMG-CoA reductase inhibitors**)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 12 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:196949 HCAPLUS
DOCUMENT NUMBER: 138:226745
TITLE: **HMG-CoA reductase inhibitors** stabilized by a buffer or basifying substance
INVENTOR(S): Pflaum, Zlatko; Kerc, Janez
PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 6531507 | B1 | 20030311 | US 2000-591322 | 20000609 <-- |
| AU 2000049434 | A5 | 20011217 | AU 2000-49434 | 20000609 |
| ES 2215050 | T3 | 20041001 | ES 2000-931486 | 20000609 |
| US 2003109584 | A1 | 20030612 | US 2002-298187 | 20021115 <-- |
| US 6806290 | B2 | 20041019 | | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| EP 2000-931486 | A | 20000609 |
| US 2000-591322 | A | 20000609 |
| WO 2000-IB773 | A | 20000609 |

AB The present invention relates to a **HMG-CoA reductase inhibitor** which is stabilized by forming a homogeneous **composition** with a buffering substance or a basifying substance. This homogeneous **composition** is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. **Pravastatin** Na is stabilized by addition of Na2CO3.

IT **81093-37-0, Pravastatin 81131-70-6, Pravastatin sodium**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**HMG-CoA reductase inhibitors** stabilized by a buffer or basifying substance)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-

trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,
(βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 13 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:133112 HCAPLUS
DOCUMENT NUMBER: 138:175886
TITLE: Oral pharmaceutical **composition** containing a combination of PPARα and **HMG-CoA reductase inhibitor**
INVENTOR(S): Vanderbist, Francis; Deboeck, Arthur; Baudier, Philippe; Sereno, Antonio
PATENT ASSIGNEE(S): Galephar M/F, Belg.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003013608 | A1 | 20030220 | WO 2002-BE135 | 20020807 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| WO 2003013607 | A1 | 20030220 | WO 2001-BE147 | 20010907 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2456732 | AA | 20030220 | CA 2002-2456732 | 20020807 |
| EP 1414496 | A1 | 20040506 | EP 2002-766983 | 20020807 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| US 2005032878 | A1 | 20050210 | US 2004-486219 | 20040908 <-- |
| PRIORITY APPLN. INFO.: | | | WO 2001-BE133 W | 20010807 |
| | | | WO 2001-BE147 W | 20010907 |
| | | | WO 2002-BE135 W | 20020807 |

AB Disclosed is an oral pharmaceutical **composition** containing, in the same pharmaceutical form, effective amts. of a **HMG-CoA reductase inhibitor** derivative and of peroxisome proliferator activated receptor-α (PPARα), especially fenofibrate. Also described is the use of some inactive ingredients which allow to improve the dissoln. and/or bioavailability of the drugs from the said **composition** A capsule containing simvastatin 20, fenofibrate 200, Gelucire 44/14 350, vitamin E TPGS 20, polyethylene glycol 6000 30, buthylhydroxyanisol 0.08 mg was prepared

IT **81093-37-0**, **Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical **composition** containing PPARα, **HMG -CoA reductase inhibitor**, glyceride derivs., and other excipients)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 14 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:133111 HCAPLUS
DOCUMENT NUMBER: 138:175885
TITLE: Oral pharmaceutical **composition** containing a combination of fenofibrate and a **HMG-CoA reductase inhibitor**
INVENTOR(S): Vanderbist, Francis; Deboeck, Arthur; Baudier, Philippe
PATENT ASSIGNEE(S): Galephar M/F, Belg.
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003013607 | A1 | 20030220 | WO 2001-BE147 | 20010907 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2456732 | AA | 20030220 | CA 2002-2456732 | 20020807 |
| WO 2003013608 | A1 | 20030220 | WO 2002-BE135 | 20020807 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1414496 | A1 | 20040506 | EP 2002-766983 | 20020807 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

| | | | | | |
|---|---|---|---|---|---|
| US 2005032878 | A1 | 20050210 | US 2004-486219 | | 20040908 <-- |
| PRIORITY APPLN. INFO.: | | | WO 2001-BE133 | W | 20010807 |
| | | | WO 2001-BE147 | A | 20010907 |
| | | | WO 2002-BE135 | W | 20020807 |

AB Disclosed is an oral pharmaceutical **composition** containing, in the same pharmaceutical form, effective amts. of a HMG-GoA **reductase inhibitor** derivative and of fenofibrate. Also described is the use of some inactive ingredients which allow to improve the dissoln. and/or bioavailability of the drugs from the said **composition** A capsule containing simvastatin 20, fenofibrate 200, Gelucire 44/14 350, vitamin E TPGA 20, polyethylene glycol 30, buthylhydroxyanisole 0.08 mg was formulated.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical **composition** containing a combination of fenofibrate and a **HMG-CoA reductase inhibitor** with excipients)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 15 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:869578 HCAPLUS
DOCUMENT NUMBER: 137:358182
TITLE: Sustained release pharmaceutical **composition** and method of releasing pharmaceutically active agent
INVENTOR(S): Shah, Rajen; Patel, Arun Parmanand; Sandry, Roy Thomas
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont. of U.S. Ser. No. 415,313.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| US 2002169145 | A1 | 20021114 | US 2002-100656 | | 20020318 <-- |
| PRIORITY APPLN. INFO.: | | | US 1998-155253P | P | 19981014 |
| | | | US 1999-415313 | A1 | 19991008 |

AB The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical **compns.** which contain therapeutic amts. of a pharmaceutically active agent, hydroxypropyl Me cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average mol. weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average mol. weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average mol. weight ranging from 100,000 to 500,000.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained release pharmaceutical **composition** and method of releasing pharmaceutically active agent)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L22 ANSWER 16 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:868726 HCAPLUS
DOCUMENT NUMBER: 137:358160
TITLE: Pharmaceutical **composition** comprising a **HMG-CoA reductase inhibitor**
INVENTOR(S): Hedge, Deepak; Kulkarni, Sushrut
PATENT ASSIGNEE(S): Biochemie Gesellschaft m.b.H., Austria
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002089788 | A2 | 20021114 | WO 2002-EP4891 | 20020503 |
| WO 2002089788 | A3 | 20021212 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

| | | | | |
|---|---|---|---|---|
| EP 1392277 | A2 | 20040303 | EP 2002-735331 | 20020503 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 2004167085 | A1 | 20040826 | US 2004-476816 | 20040413 <-- |
| US 6911472 | B2 | 20050628 | | |
| PRIORITY APPLN. INFO.: | | | GB 2001-11077 | A 20010504 |
| | | | WO 2002-EP4891 | W 20020503 |

AB A pharmaceutical **composition** comprising an **HMG-CoA reductase inhibitor**, i.e., a statin, as an active ingredient, and an aminosugar, as a pH adjusting (basifying) agent, is described. **Compns.** comprising dehydroepiandrosterone (DHEA), a desquamating agent selected from retinoids, acylated salicylic acid derivs. or **HMG-CoA reductase inhibitors**, and sugar derivs., and comprising germs for a koji-making raw material and monacolin K, are excluded. For example, tablets were obtained containing **pravastatin sodium** 10.00%, lactose (filler) 68.20%, microcryst. cellulose (filler) 13.50%, polyvinylpyrrolidone (binder) 0.50%, croscarmellose **sodium** (disintegrant) 6.00%, Mg stearate (lubricant) 1.00%, and Meglumine (pH adjusting agent) 0.80%. Tablets were stable for > 1 mo under normal environment humidity conditions.

IT **81093-37-0, Pravastatin 81131-70-6, Sodium pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of tablets of **HMG-CoA reductase inhibitors** containing aminosugar as pH adjusting agent)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L22 ANSWER 17 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:777650 HCAPLUS
DOCUMENT NUMBER: 137:299910
TITLE: Therapeutic combinations containing COX-2 **inhibitors** for cardiovascular and inflammatory diseases treatment
INVENTOR(S): Seibert, Karen; Keller, Bradley T.; Isakson, Peter C.; Krul, Elaine S.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 316 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002078626 | A2 | 20021010 | WO 2002-US9346 | 20020328 |
| WO 2002078626 | A3 | 20040429 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2442328 | AA | 20021010 | CA 2002-2442328 | 20020328 |
| US 2003199482 | A1 | 20031023 | US 2002-107809 | 20020328 <-- |
| EP 1435956 | A2 | 20040714 | EP 2002-725362 | 20020328 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| CN 1527709 | A | 20040908 | CN 2002-810210 | 20020328 |
| JP 2005507854 | T2 | 20050324 | JP 2002-576894 | 20020328 |
| US 2004186154 | A1 | 20040923 | US 2004-473045 | 20040506 <-- |

PRIORITY APPLN. INFO.: US 2001-279239P P 20010328
WO 2002-US9346 W 20020328

AB The present invention provides therapeutic combinations and methods for

treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises an ASBT **inhibitor** combined with COX-2 **inhibitor.** A further therapeutic combination comprises an ASBT **inhibitor**, a COX-2 **inhibitor** and an HMG Co-A **reductase inhibitor.** Another therapeutic combination comprises a chromene COX-2 **inhibitor** and an HMG Co-A **reductase inhibitor.** Thus, a tablet **composition** contained benzothiepine 5, celecoxib 20, lactose 54, microcryst. cellulose 15, HPMC 3, Croscarmellose **sodium** 2, and Mg stearate 1 mg/tablet.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic combinations containing COX-2 **inhibitors** for cardiovascular and inflammatory diseases treatment)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L22 ANSWER 18 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:574956 HCAPLUS
DOCUMENT NUMBER: 137:129904
TITLE: Combinations of peroxisome proliferator-activated receptor activators and sterol absorption **inhibitors** for treatment of vascular diseases
INVENTOR(S): Kosoglou, Teddy; Davis, Harry R.; Picard, Gilles Jean Bernard
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002058732 | A2 | 20020801 | WO 2002-US2009 | 20020125 |
| WO 2002058732 | A3 | 20030703 | | |
| WO 2002058732 | B1 | 20030912 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,

MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| CA 2434682 | AA | 20020801 | CA 2002-2434682 | 20020125 |
| EP 1353696 | A2 | 20031022 | EP 2002-714773 | 20020125 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2002006654 | A | 20040225 | BR 2002-6654 | 20020125 |
| EP 1413331 | A2 | 20040428 | EP 2004-161 | 20020125 |
| EP 1413331 | A3 | 20040630 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004521893 | T2 | 20040722 | JP 2002-559066 | 20020125 |
| EP 1541175 | A2 | 20050615 | EP 2005-3029 | 20020125 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| ZA 2003005692 | A | 20041025 | ZA 2003-5692 | 20030723 |
| ZA 2003005694 | A | 20041025 | ZA 2003-5694 | 20030723 |
| ZA 2003005693 | A | 20050209 | ZA 2003-5693 | 20030723 |
| NO 2003003355 | A | 20030725 | NO 2003-3355 | 20030725 |
| US 2005153952 | A1 | 20050714 | US 2004-998400 | 20041129 <-- |

| | | |
|---|---|---|
| PRIORITY APPLN. INFO.: | US 2001-264396P | P 20010126 |
| | US 2001-323839P | P 20010921 |
| | US 2001-264275P | P 20010126 |
| | US 2001-264600P | P 20010126 |
| | US 2001-323842P | P 20010921 |
| | EP 2002-707500 | A3 20020125 |
| | EP 2002-714773 | A3 20020125 |
| | US 2002-57323 | A3 20020125 |
| | WO 2002-US2009 | W 20020125 |
| | US 2002-136968 | A3 20020501 |

OTHER SOURCE(S): MARPAT 137:129904

AB The present invention provides **compns.**, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor (PPAR) activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption **inhibitor** which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. A tablet contained azetidinone 10, lactose monohydrate 55, microcryst. cellulose 20, povidone 4, croscarmellose **sodium** 8, **sodium** lauryl sulfate 2, and magnesium stearate 1 mg. The tablet can be coadministered with a tablets containing a PPAR activator such as ezetimibe. Synthetic preparation of ezetimibe from fluorohenylazetidinone derivs. is described. The coadministration of 10 mg of ezetimibe with 200 mg of fenofibrate was well tolerated and caused a significant reduction in LDL-C as compared to either drug alone or placebo.

IT **81093-37-0, Pravastatin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of peroxisome proliferator-activated receptor activators and sterol absorption **inhibitors** for treatment of vascular diseases)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 19 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:574955 HCAPLUS
DOCUMENT NUMBER: 137:129903
TITLE: Combinations of azetidinone sterol absorption **inhibitor**(s) with cardiovascular agent(s) for the treatment of vascular conditions
INVENTOR(S): Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002058731 | A2 | 20020801 | WO 2002-US1196 | 20020125 |
| WO 2002058731 | A3 | 20031120 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2434436 | AA | 20020801 | CA 2002-2434436 | 20020125 |
| US 2003069221 | A1 | 20030410 | US 2002-57339 | 20020125 <-- |
| EP 1385548 | A2 | 20040204 | EP 2002-707500 | 20020125 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2002006644 | A | 20040225 | BR 2002-6644 | 20020125 |
| EP 1413331 | A2 | 20040428 | EP 2004-161 | 20020125 |
| EP 1413331 | A3 | 20040630 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004517919 | T2 | 20040617 | JP 2002-559065 | 20020125 |
| EP 1541175 | A2 | 20050615 | EP 2005-3029 | 20020125 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| ZA 2003005692 | A | 20041025 | ZA 2003-5692 | 20030723 |

| | | | | | |
|---|---|---|---|---|---|
| ZA 2003005694 | A | 20041025 | ZA 2003-5694 | | 20030723 |
| ZA 2003005693 | A | 20050209 | ZA 2003-5693 | | 20030723 |
| NO 2003003358 | A | 20030912 | NO 2003-3358 | | 20030725 |
| US 2004097482 | A1 | 20040520 | US 2003-639900 | | 20030813 <-- |
| US 2005153952 | A1 | 20050714 | US 2004-998400 | | 20041129 <-- |
| PRIORITY APPLN. INFO.: | | | US 2001-264275P | P | 20010126 |
| | | | US 2001-264396P | P | 20010126 |
| | | | US 2001-264600P | P | 20010126 |
| | | | US 2001-323842P | P | 20010921 |
| | | | US 2001-323839P | P | 20010921 |
| | | | EP 2002-707500 | A3 | 20020125 |
| | | | EP 2002-714773 | A3 | 20020125 |
| | | | US 2002-57323 | A3 | 20020125 |
| | | | US 2002-57646 | A1 | 20020125 |
| | | | WO 2002-US1196 | W | 20020125 |
| | | | US 2002-136968 | A3 | 20020501 |

OTHER SOURCE(S): MARPAT 137:129903
GI




I

AB The present invention provides **compns.**, therapeutic combinations and methods including: (a) at least one sterol absorption **inhibitor** and (b) at least one cardiovascular agent different from the sterol absorption **inhibitor**, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prepared containing cardiovascular agents which can be coadministered with formulations containing, e.g., I. The preparation of I was given.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of azetidinone sterol absorption **inhibitor**(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 20 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:428761 HCAPLUS
DOCUMENT NUMBER: 137:11000
TITLE: Pharmaceutical **compositions** containing angiotensin receptor blockers for treating sexual dysfunction
INVENTOR(S): Sahota, Pritam Singh
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002043807 | A2 | 20020606 | WO 2001-EP13976 | 20011129 |
| WO 2002043807 | A3 | 20030814 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| CA 2430924 | AA | 20020606 | CA 2001-2430924 | 20011129 |
| AU 2002026365 | A5 | 20020611 | AU 2002-26365 | 20011129 |
| EP 1353727 | A2 | 20031022 | EP 2001-995680 | 20011129 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004514703 | T2 | 20040520 | JP 2002-545776 | 20011129 |
| US 2002107236 | A1 | 20020808 | US 2001-8445 | 20011203 <-- |
| US 2004087484 | A1 | 20040506 | US 2003-433189 | 20030624 <-- |

| PRIORITY APPLN. INFO.: | | | |
|---|---|---|---|
| US 2000-250540P | P | 20001201 | |
| WO 2001-EP13976 | W | 20011129 | |

AB The present invention relates to methods of treating sexual dysfunction associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an **HMG-CoA reductase inhibitor.** A film-coated tablet contained valsartan 8.00, microcryst. cellulose 54.00, crospovidone 20.00, colloidal silica 1.50, magnesium stearate 4.5, and Diolack pale red 00F34899 7.00 mg.

IT **81093-37-0, PRAVASTATin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical **compns.** containing angiotensin receptor blockers for treating sexual dysfunction)
RN 81093-37-0 . HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L22 ANSWER 21 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:392237 HCAPLUS
DOCUMENT NUMBER: 136:401651
TITLE: Preparation of fused pyridine derivatives as **HMG-CoA reductase inhibitors**
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE | |
|---|---|---|---|---|---|---|
| US 2002061901 | A1 | 20020523 | US 2001-8154 | | 20011204 | <-- |
| US 6620821 | B2 | 20030916 | | | | |
| US 2002028826 | A1 | 20020307 | US 2001-875218 | | 20010606 | <-- |
| US 2004024216 | A1 | 20040205 | US 2003-602753 | | 20030624 | <-- |
| PRIORITY APPLN. INFO.: | | | US 2000-211594P | P | 20000615 | |
| | | | US 2001-875218 | A2 | 20010606 | |
| | | | US 2001-8154 | A3 | 20011204 | |

OTHER SOURCE(S): MARPAT 136:401651
GI




I




II

AB The title compds. I and their pharmaceutically acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH2CR7(OH)CH2CO2R3 or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH2)x and/or (CH2)y together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H or lower alkyl; R4 = H, halo, CF3, OH, alkyl, alkoxy, CO2H, (un)substituted NH2, cyano, (un)substituted CONH2, etc.; R7 = H, alkyl]. The compds. are **HMG -CoA reductase inhibitors**, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement therapy, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Prepns. of several compds. are described. For instance, a multistep synthesis of fused pyridine derivative II is reported. Compds. I may be used in a manner similar to atorvastatin, **pravastatin**, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain pharmacol. classes, as **inhibitors** of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic **compns.** also containing; preparation of fused pyridine derivs. as **HMG-CoA reductase inhibitors**)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 22 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:184896 HCAPLUS
DOCUMENT NUMBER: 136:236854
TITLE: Medicinal **compositions** for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and **HMG-CoA reductase inhibitors**
INVENTOR(S): Kohama, Takafumi; Inaba, Toshimori
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|---|---|---|---|---|---|
| WO 2002020009 | A1 | 20020314 | WO 2001-JP7438 | 20010829 | |
| W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA | | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | | |
| AU 2001082541 | A5 | 20020322 | AU 2001-82541 | 20010829 | |
| CA 2420951 | AA | 20030228 | CA 2001-2420951 | 20010829 | |
| EP 1314423 | A1 | 20030528 | EP 2001-961177 | 20010829 | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR | | | | | |
| NZ 524406 | A | 20040625 | NZ 2001-524406 | 20010829 | |
| BR 2001013523 | A | 20040629 | BR 2001-13523 | 20010829 | |
| RU 2246302 | C2 | 20050220 | RU 2003-105835 | 20010829 | |
| US 2002055533 | A1 | 20020509 | US 2001-943712 | 20010831 | <-- |
| JP 2002145774 | A2 | 20020522 | JP 2001-262600 | 20010831 | |
| ZA 2003001543 | A | 20040609 | ZA 2003-1543 | 20030225 | |
| NO 2003000946 | A | 20030408 | NO 2003-946 | 20030228 | |
| US 2004092571 | A1 | 20040513 | US 2003-702930 | 20031105 | <-- |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| JP 2000-265082 | A | 20000901 |
| US 2000-230601P | P | 20000906 |
| WO 2001-JP7438 | W | 20010829 |
| US 2001-943712 | B1 | 20010831 |

AB Disclosed are medicinal **compns.** for administering N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmacol. acceptable salt and an **HMG-CoA reductase inhibitor** either at the same time or sep. after a definite period of time. Blood lipid-lowering effect

of oral administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate (I) 30 and **pravastatin** 3 mg/kg in hamsters was examined Also, tablet containing I 30, **sodium pravastatin** 10, lactose 408, corn starch 50, and magnesium stearate 2 mg was formulated.

IT **81093-37-0, Pravastatin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal **compns.** for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and **HMG-CoA reductase inhibitors**)
RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **81131-70-6, Sodium pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal **compns.** for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and **HMG-CoA reductase inhibitors**)
RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 23 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:171683 HCAPLUS
DOCUMENT NUMBER: 136:205466
TITLE: Medicinal **compositions** containing **HMG-CoA reductase inhibitors** and angiotensin II receptor antagonists for preventing or treating heart failure
INVENTOR(S): Lee, Tsung Ming; Lee, Bai-Ching; Su, Shen-Fang; Hsiao, Chia-Ling; Chu, Chia-Wei
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002017913 | A1 | 20020307 | WO 2001-JP7437 | 20010829 |
| W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, ZA | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| AU 2001084413 | A5 | 20020313 | AU 2001-84413 | 20010829 |
| JP 2002145770 | A2 | 20020522 | JP 2001-259399 | 20010829 |
| CA 2420844 | AA | 20030228 | CA 2001-2420844 | 20010829 |
| EP 1314425 | A1 | 20030528 | EP 2001-963398 | 20010829 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR | | | | |
| US 2003181500 | A1 | 20030925 | US 2003-374171 | 20030226 <-- |
| US 2005059720 | A1 | 20050317 | US 2004-977645 | 20041029 <-- |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| JP 2000-260949 | A | 20000830 |
| WO 2001-JP7437 | W | 20010829 |
| US 2003-374171 | A3 | 20030226 |

AB Disclosed are medicinal **compns.** comprising an **HMG-CoA reductase inhibitor** selected from the group consisting of **pravastatin**, simvastatin, lovastatin, pitavastatin and ZD-4522, and an angiotensin II receptor antagonist optionally together with a calcium channel blocker. The preventive effect of administration of **pravastatin** 10, losartan 50, and amlodipine 5 mg/day for 6 mo on left ventricle hypertrophy in patients was examined

IT **81093-37-0, Pravastatin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal **compns.** containing **HMG-CoA reductase inhibitors** and angiotensin II receptor antagonists for preventing or treating heart failure)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **81131-70-6, Pravastatin sodium** salt
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal **compns.** containing **HMG-CoA reductase inhibitors** and angiotensin II receptor antagonists for preventing or treating heart failure)
RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 24 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:661287 HCAPLUS
DOCUMENT NUMBER: 135:216008
TITLE: P-glycoprotein modifier-containing medicinal **compositions** to be delivered to the large intestine
INVENTOR(S): Tanida, Norifumi; Goto, Takeshi; Kurosaki, Yuji
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001064253 | A1 | 20010907 | WO 2001-JP1546 | 20010301 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001036009 | A5 | 20010912 | AU 2001-36009 | 20010301 |
| EP 1260233 | A1 | 20021127 | EP 2001-908178 | 20010301 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 2003158097 | A1 | 20030821 | US 2002-220551 | 20021121 <-- |
| PRIORITY APPLN. INFO.: | | | JP 2000-57630 A | 20000302 |
| | | | WO 2001-JP1546 W | 20010301 |

AB Disclosed are novel medicinal **compns.** aiming at delivering a medicine to a specific site of the large intestine; and prepns. for intestinal administration with the use of the same. P-glycoprotein enhancers and **inhibitors** in the **compns.** allow specific drug delivery in the lower or upper intestine. A tablet was formulated containing betamethasone **sodium** phosphate 2, verapamil (as P-glycoprotein **inhibitor**) 1, crystalline cellulose 10, lactose 81, crospovidone 5, and Mg stearate 1 part was coated with a coating **composition** containing Eudragit E 7,ethanol 70, water 19.5, and talc 3.5 parts.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(P-glycoprotein modifiers for drug delivery to intestine)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 25 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:31357 HCAPLUS
DOCUMENT NUMBER: 134:80814
TITLE: Cyclooxygenase **inhibitor** and **HMG-CoA reductase inhibitor** as

medicinal **compositions** for treating colorectal cancer

INVENTOR(S): Tanida, Norifumi; Goto, Takeshi; Tomizawa, Naoko
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001002014 | A1 | 20010111 | WO 2000-JP4327 | 20000630 |
| W: AU, CA, CN, ID, JP, KR, US, VN | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2373940 | AA | 20010111 | CA 2000-2373940 | 20000630 |
| EP 1197228 | A1 | 20020417 | EP 2000-942407 | 20000630 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| US 6620834 | B1 | 20030916 | US 2002-19469 | 20020415 <-- |

PRIORITY APPLN. INFO.: JP 1999-188408 A 19990702
WO 2000-JP4327 W 20000630

AB Medicinal **compns.** for colorectal cancer to be administered to the large intestine by taking advantage of prepns. disintegrating in the large intestine, characterized by containing a cyclooxygenase **inhibitor** and an **HMG-CoA reductase inhibitor.** These **compns.** are appropriate for inhibiting the postoperative liver metastasis and recurrence of colorectal cancer.

IT **81093-37-0, Pravastatin**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase **inhibitor** and **HMG-CoA reductase inhibitor** as medicinal **compns.** for treating colorectal cancer)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 26 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:401689 HCAPLUS
DOCUMENT NUMBER: 131:49480
TITLE: Improved **HMG-CoA reductase inhibitor** extended release formulation
INVENTOR(S): Chen, Chih-ming; Chou, Joseph; Wong, David
PATENT ASSIGNEE(S): Andrx Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9930692 | A1 | 19990624 | WO 1998-US25766 | 19981204 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 5916595 | A | 19990629 | US 1997-989253 | 19971212 <-- |
| CA 2315329 | AA | 19990624 | CA 1998-2315329 | 19981204 |
| AU 9916275 | A1 | 19990705 | AU 1999-16275 | 19981204 |
| AU 737962 | B2 | 20010906 | | |
| EP 1035842 | A1 | 20000920 | EP 1998-960752 | 19981204 |
| R: AT, CH, DE, ES, FR, GB, LI, PT, IE, FI | | | | |
| JP 2002508311 | T2 | 20020319 | JP 2000-538675 | 19981204 |
| US 2004029962 | A1 | 20040212 | US 2003-603254 | 20030625 <-- |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 1997-989253 | A | 19971212 |
| WO 1998-US25766 | W | 19981204 |
| US 1999-339494 | B1 | 19990624 |
| US 1999-435576 | A1 | 19991108 |

AB A controlled release dosage formulation is described which is based on a combination of: (a) a compressed tablet core which contains an alkyl ester of a hydroxy-substituted naphthalene derivative, a pharmaceutically acceptable, water-swellable polymer and an osmotic agent; and (b) an outer coating layer which completely covers the osmotic core and comprises a pH-sensitive coating agent and a water-insol. polymer. A tablet core containing lovastatin 11.99, Polyox WSR Coagulant 4.50, Polyox WSR N-80 17.98, lactose (anhydrous) 50.65, Na lauryl sulfate 3.00, fumed silica 0.45, and Myvaplex 600 1.80 %, was coated with a seal-coating **composition** containing Opadry clear 2.81 and NaCl 0.93 %; an inner coating **compn**. containing hydroxypropyl Me cellulose phthalate 2.27, talc 0.78, acetyl tri-Bu citrate 0.22, and sugars 0.62 %; and an outer coating **compn**. containing cellulose acetate 1, Eudragit S100 0.34, triacetin 0.08, polyethylene glycol 0.09, and sugars 0.5 %.

IT **81093-37-0, Pravastatin**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release tablets containing **HMG-CoA reductase inhibitors**)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-

trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,
(βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 27 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:113552 HCAPLUS
DOCUMENT NUMBER: 130:173009
TITLE: Combinations of **HMG-CoA reductase inhibitors** and nicotinic acid and methods for treating hyperlipidemia
INVENTOR(S): Bova, David J.; Dunne, Josephine
PATENT ASSIGNEE(S): Kos Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9906046 | A1 | 19990211 | WO 1998-US15989 | 19980731 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2001006644 | A1 | 20010705 | US 1997-903871 | 19970731 <-- |
| CA 2297764 | AA | 19990211 | CA 1998-2297764 | 19980731 |
| AU 9886800 | A1 | 19990222 | AU 1998-86800 | 19980731 |
| EP 1003515 | A1 | 20000531 | EP 1998-938227 | 19980731 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| BR 9815549 | A | 20040622 | BR 1998-15549 | 19980731 |
| NO 2000000407 | A | 20000316 | NO 2000-407 | 20000127 |
| PRIORITY APPLN. INFO.: | | | US 1997-903871 A | 19970731 |
| | | | WO 1998-US15989 W | 19980731 |

AB The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixts. thereof in an extended release form and an **HMG-**

**CoA reductase inhibitor**, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis. The present invention also relates to methods of altering serum lipids in subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in normolipidemics diagnosed with or predisposed to cardiovascular disease, and atherosclerosis, by administering such oral solid pharmaceutical combinations once per day as a single dose during the evening hours, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis, or without causing in at least an appreciable number of individuals drug-induced hepatotoxicity, myopathy or rhabdomyolysis to such a level that discontinuation of such therapy would be required. More particularly, the present invention concerns oral solid pharmaceutical combinations comprised of, for example, (1) an **HMG-CoA reductase inhibitor** for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixts. thereof, and (3) a swelling agent to form a sustained release **composition** for extended release of the nicotinic acid or nicotinic acid compound or mixts. thereof for nocturnal or evening dosing for reducing serum lipids and increasing HDL-cholesterol. In accordance with the present invention, and by way of example, a **composition** for oral administration during the evening hours to alter serum lipids comprised of nicotinic acid and hydroxypropyl Me cellulose in the form of an extended or sustained release tablet or caplet coated with a coating comprising an **HMG-CoA reductase inhibitor** in immediate release form is disclosed. Also in accordance with the present invention, the pharmaceutical combinations may include a nonsteroidal anti-inflammatory agent for reducing the capacity of nicotinic acid or nicotinic acid compds. to provoke flushing reactions in individuals.

IT **81093-37-0, Pravastatin**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral dosage forms containing **HMG-CoA reductase inhibitors** and nicotinate for treating hyperlipidemia)

RN 81093-37-0 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 28 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN.

ACCESSION NUMBER: 1998:98321 HCAPLUS
DOCUMENT NUMBER: 128:196661
TITLE: Antithrombotic and antiatherogenic pharmaceutical **composition** including a thienopyridine derivative and an **HMG-CoA reductase inhibitor**
INVENTOR(S): Daste, Georges; Herbert, Jean-Marc
PATENT ASSIGNEE(S): Sanofi, Fr.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9804259 | A1 | 19980205 | WO 1997-FR1353 | 19970721 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| FR 2751540 | A1 | 19980130 | FR 1996-9474 | 19960726 |
| FR 2751540 | B1 | 19981016 | | |
| ZA 9706247 | A | 19990115 | ZA 1997-6247 | 19970715 |
| CA 2261099 | AA | 19980205 | CA 1997-2261099 | 19970721 |
| CA 2261099 | C | 20030415 | | |
| AU 9738526 | A1 | 19980220 | AU 1997-38526 | 19970721 |
| AU 725949 | B2 | 20001026 | | |
| EP 914124 | A1 | 19990512 | EP 1997-935593 | 19970721 |
| EP 914124 | B1 | 20040121 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | |
| BR 9710560 | A | 19990817 | BR 1997-10560 | 19970721 |
| CN 1228698 | A | 19990915 | CN 1997-197539 | 19970721 |
| CN 1109547 | B | 20030528 | | |
| JP 2000500781 | T2 | 20000125 | JP 1998-508545 | 19970721 |
| JP 3553610 | B2 | 20040811 | | |
| NZ 333826 | A | 20000929 | NZ 1997-333826 | 19970721 |
| RU 2176504 | C2 | 20011210 | RU 1999-103623 | 19970721 |
| EE 3853 | B1 | 20021015 | EE 1999-28 | 19970721 |
| AT 258052 | E | 20040215 | AT 1997-935593 | 19970721 |
| PT 914124 | T | 20040531 | PT 1997-935593 | 19970721 |
| ES 2214632 | T3 | 20040916 | ES 1997-935593 | 19970721 |
| CZ 294664 | B6 | 20050216 | CZ 1999-176 | 19970721 |
| PL 188739 | B1 | 20050429 | PL 1997-331339 | 19970721 |
| KR 2000029484 | A | 20000525 | KR 1999-700501 | 19990122 |
| US 6218403 | B1 | 20010417 | US 1999-230299 | 19990122 <-- |
| NO 9900321 | A | 19990322 | NO 1999-321 | 19990125 |
| HK 1019405 | A1 | 20031017 | HK 1999-104578 | 19991101 |

PRIORITY APPLN. INFO.: FR 1996-9474 A 19960726
WO 1997-FR1353 W 19970721

OTHER SOURCE(S): MARPAT 128:196661
GI



I

AB A pharmaceutical **composition** containing (a) a thienopyridine derivative (I; R = H, C1-4 alkoxycarbonyl) or a pharmaceutically acceptable salt thereof; and (b) an **HMG-CoA-reductase inhibitor**, is disclosed. A combination of 5 mg/kg clopidogrel and 5 mg/kg simavastatin had synergistic effect and inhibited the formation of thrombose by 72% in rabbits. A 2-layered pharmaceutical tablet contained ticlopidine hydrochloride 200.00, microcryst. cellulose 69.88, maize starch 31.20, polyvidone 6.24, citric acid 3.12, stearic acid 0.78, magnesium stearate 0.78 mg in the first layer and simavastatin 20.00, butydroyxanisole 0.04, ascorbic acid 5.00, citric acid 2.50, microcryst. cellulose 10.00, maize starch 20.00, lactose 141.50, magnesium stearate 1.00, methylhydroy Pr cellulose 1.65, hydroxypropyl cellulose 1.65, titanium dioxide 1.50, talc 0.60, yellow ferric oxide 0.092, and red ferric oxide 0.023 mg in the second layer.

IT **81131-70-6, Pravastatin Sodium**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antithrombotic and antiatherogenic pharmaceutical **composition** including thienopyridine derivative and **HMG-CoA reductase inhibitor**)

RN 81131-70-6 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 29 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:315691 HCAPLUS
DOCUMENT NUMBER: 126:334419
TITLE: Pharmaceutical **compositions** for preventing a second heart attack containing an **HMG CoA reductase inhibitor**
INVENTOR(S): Olukotun, Adeove Y.; Alexander, John C.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 8 pp., Cont.-in-part of U.S. Ser. No. 824,679, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5622985 | A | 19970422 | US 1995-424984 | 19950419 <-- |
| CA 2172884 | AA | 19961020 | CA 1996-2172884 | 19960328 |
| EP 738512 | A1 | 19961023 | EP 1996-106104 | 19960418 |
| EP 738512 | B1 | 20030702 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| AU 9650741 | A1 | 19961031 | AU 1996-50741 | 19960418 |
| AU 715181 | B2 | 20000120 | | |
| AT 244006 | E | 20030715 | AT 1996-106104 | 19960418 |
| PT 738512 | T | 20031128 | PT 1996-106104 | 19960418 |
| ES 2202393 | T3 | 20040401 | ES 1996-106104 | 19960418 |
| JP 08291082 | A2 | 19961105 | JP 1996-98084 | 19960419 |
| PRIORITY APPLN. INFO.: | | | US 1990-536367 | B1 19900611 |
| | | | US 1992-824679 | B2 19920123 |
| | | | US 1995-424984 | A 19950419 |

AB A pharmaceutical **compns.** is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an **HMG CoA reductase inhibitor** such as **pravastatin** (I), alone or in combination with an ACE **inhibitor.** A tablet contained I 7, lactose 67, microcryst. cellulose 20, croscarmellose **sodium** 2, magnesium stearate 2, and magnesium oxide 3 parts.

IT **81093-37-0, Pravastatin**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical **compns.** for preventing second heart attack containing **HMG CoA reductase inhibitor**)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 30 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:178769 HCAPLUS
DOCUMENT NUMBER: 126:176899
TITLE: Synergistic combination comprising an insulin sensitizer and a **HMG-CoA reductase inhibitor** for treating arteriosclerosis
INVENTOR(S): Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|---|---|---|---|---|---|
| EP 753298 | A1 | 19970115 | EP 1996-304924 | 19960703 | |
| EP 753298 | B1 | 20011121 | | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | | |
| CA 2180296 | AA | 19970104 | CA 1996-2180296 | 19960702 | |
| NO 9602784 | A | 19970106 | NO 1996-2784 | 19960702 | |
| AU 9656261 | A1 | 19970116 | AU 1996-56261 | 19960702 | |
| AU 706628 | B2 | 19990617 | | | |
| JP 09071540 | A2 | 19970318 | JP 1996-172137 | 19960702 | |
| JP 3651816 | B2 | 20050525 | | | |
| US 5798375 | A | 19980825 | US 1996-676090 | 19960702 | <-- |
| IL 118778 | A1 | 19990714 | IL 1996-118778 | 19960702 | |
| RU 2158607 | C2 | 20001110 | RU 1996-112769 | 19960702 | |
| TW 474809 | B | 20020201 | TW 1996-85107984 | 19960702 | |
| ZA 9605650 | A | 19970127 | ZA 1996-5650 | 19960703 | |
| CN 1148492 | A | 19970430 | CN 1996-112170 | 19960703 | |
| CN 1089584 | B | 20020828 | | | |
| CZ 286832 | B6 | 20000712 | CZ 1996-1982 | 19960703 | |
| AT 209046 | E | 20011215 | AT 1996-304924 | 19960703 | |
| ES 2165474 | T3 | 20020316 | ES 1996-304924 | 19960703 | |
| PT 753298 | T | 20020328 | PT 1996-304924 | 19960703 | |
| US 6159997 | A | 20001212 | US 1998-61446 | 19980416 | <-- |
| HK 1011928 | A1 | 20020628 | HK 1998-113080 | 19981210 | |
| JP 2004075691 | A2 | 20040311 | JP 2003-359698 | 20031020 | |
| JP 2004250455 | A2 | 20040909 | JP 2004-96229 | 20040329 | |
| PRIORITY APPLN. INFO.: | | | JP 1995-167291 A | 19950703 | |

JP 1996-172137 A3 19960702
US 1996-676090 A3 19960702

AB A combination of 1 or more HMG-CoAreductase **inhibitors** (e.g., **pravastatin**, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with 1 or more insulin sensitizers (e.g., troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]ethoxy)benzyl}thiazolidine-2,4-dione) exhibits a synergistic effect and is better at prevention and/or treatment of arteriosclerosis and/or xanthoma than is either of the components of the combination alone. Thus, **pravastatin sodium** 0.5, troglitazone 20, Crospovidone 1.5, and Na lauryl sulfate 0.2 g were blended and the mixture was divided among 100 capsules, each containing 5 mg **pravastatin sodium** and 200 mg troglitazone. The preparation of some thiazolidine-2,4-diones is reported.

IT **81093-37-0, Pravastatin 81131-70-6, Pravastatin sodium**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic **composition** containing insulin sensitizer and **HMG -CoA reductase inhibitor** for treatment of arteriosclerosis)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 81131-70-6 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L22 ANSWER 31 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:701531 HCAPLUS
DOCUMENT NUMBER: 125:339030
TITLE: Use of **HMG CoA reductase inhibitor** to prevent second heart attack
INVENTOR(S): Olukotun, Adeoye Y.; Alexander, John C.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 738512 | A1 | 19961023 | EP 1996-106104 | 19960418 |
| EP 738512 | B1 | 20030702 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| US 5622985 | A | 19970422 | US 1995-424984 | 19950419 <-- |
| PRIORITY APPLN. INFO.: | | | US 1995-424984 A | 19950419 |
| | | | US 1990-536367 B1 | 19900611 |
| | | | US 1992-824679 B2 | 19920123 |

AB A method is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an **HMG CoA reductase inhibitor** such as **pravastatin**, alone or in combination with an ACE **inhibitor.** Tablets were formulated containing **pravastatin** 7, lactose 67, microcryst. cellulose 20, croscarmellose **sodium** 2, magnesium stearate 1, and magnesium oxide 3 parts by weight

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**HMG CoA reductase inhibitor** to prevent second heart attack and pharmaceutical **compns.** containing **HMG CoA reductase inhibitor** and other ingredients)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,

(βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L22 ANSWER 32 OF 32 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:497325 HCAPLUS
DOCUMENT NUMBER: 125:151167
TITLE: A controlled release drug delivery device comprising two-layered core and coating
INVENTOR(S): Rork, Gerald S.; Pipkin, James D.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9619201 | A1 | 19960627 | WO 1995-US16530 | 19951218 |
| W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 5582838 | A | 19961210 | US 1994-363451 | 19941222 <-- |
| CA 2206211 | AA | 19960627 | CA 1995-2206211 | 19951218 |
| AU 9644726 | A1 | 19960710 | AU 1996-44726 | 19951218 |
| AU 693313 | B2 | 19980625 | | |
| EP 801560 | A1 | 19971022 | EP 1995-943469 | 19951218 |
| EP 801560 | B1 | 20030702 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE | | | | |
| CN 1171048 | A | 19980121 | CN 1995-196988 | 19951218 |
| CN 1081916 | B | 20020403 | | |
| HU 77370 | A2 | 19980330 | HU 1997-1914 | 19951218 |
| JP 11509829 | T2 | 19990831 | JP 1995-519938 | 19951218 |
| SK 281224 | B6 | 20010118 | SK 1997-805 | 19951218 |
| RU 2168330 | C2 | 20010610 | RU 1997-112378 | 19951218 |
| PL 183615 | B1 | 20020628 | PL 1995-320792 | 19951218 |
| CZ 290802 | B6 | 20021016 | CZ 1997-1895 | 19951218 |
| AT 244001 | E | 20030715 | AT 1995-943469 | 19951218 |
| PT 801560 | T | 20031031 | PT 1995-943469 | 19951218 |
| ES 2201133 | T3 | 20040316 | ES 1995-943469 | 19951218 |
| FI 9702586 | A | 19970617 | FI 1997-2586 | 19970617 |

NO 9702880 A 19970620 NO 1997-2880 19970620
PRIORITY APPLN. INFO.: US 1994-363451 A 19941222
WO 1995-US16530 W 19951218

AB A device disclosed for the controlled delivery of a beneficial agent consisting of (1) a core comprising at least two layers, wherein at least one layer comprises a beneficial agent and a polymer which forms microscopic gel beads upon hydration and at least one layer which comprises a polymer which forms microscopic gel beads upon hydration; and (2) an impermeable, insol. coating which adheres to and surrounds the core and contains apertures which provide an area for the hydration and release of the microscopic gel beads. A two-layered core contained lovastatin (I) 40, Carbopol 974P 16, trisodium citrate 32, and lactose 16 mg/layer in the first layer and Avicel PH101 20, Carbopol 974P 8, trisodium citrate 16, and lactose 8 mg/layer in the second layer. The cores were coated with a solution of cellulose acetate butyrate 20, and triethylcitrate 3 parts in a solution of acetone:ethanol (3:1) and sprayed onto the cores to a thickness of 100μm and two holes were drilled in the face of the device.. The release profile of the two layer device were significantly improved over the single **composition** core, in that the last 20% of I was released at a more constant rate and greater than 95% of the I content was released in <20 h.

IT **81093-37-0, Pravastatin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled release drug delivery device comprising two-layered core and coating)

RN 81093-37-0 HCAPLUS
CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




```
=> s HMG-CoA reductase inhibitor
          9504 HMG
           101 HMGS
          9528 HMG
                 (HMG OR HMGS)
         41216 COA
           918 COAS
         41395 COA
                 (COA OR COAS)
         82330 REDUCTASE
          6290 REDUCTASES
         83384 REDUCTASE
                 (REDUCTASE OR REDUCTASES)
```

```
        480825 INHIBITOR
        494689 INHIBITORS
        766615 INHIBITOR
                  (INHIBITOR OR INHIBITORS)
L23       3098 HMG-COA REDUCTASE INHIBITOR
                  (HMG(W)COA(W)REDUCTASE(W)INHIBITOR)

=> s l23 and composition
        638314 COMPOSITION
        288523 COMPOSITIONS
        921226 COMPOSITION
                  (COMPOSITION OR COMPOSITIONS)
       1351441 COMPN
        544323 COMPNS
       1655583 COMPN
                  (COMPN OR COMPNS)
       2095452 COMPOSITION
                  (COMPOSITION OR COMPN)
L24        341 L23 AND COMPOSITION

=> s l24 and pravastatin sodium
          2420 PRAVASTATIN
             1 PRAVASTATINS
          2420 PRAVASTATIN
                  (PRAVASTATIN OR PRAVASTATINS)
        989801 SODIUM
            34 SODIUMS
        989810 SODIUM
                  (SODIUM OR SODIUMS)
           222 PRAVASTATIN SODIUM
                  (PRAVASTATIN(W)SODIUM)
L25         19 L24 AND PRAVASTATIN SODIUM

=> s l25 and impurity
        154887 IMPURITY
        191116 IMPURITIES
        285990 IMPURITY
                  (IMPURITY OR IMPURITIES)
L26          0 L25 AND IMPURITY

=> s l25 and py<=1998
      18939279 PY<=1998
L27          3 L25 AND PY<=1998

=> d l25 ibib abs hitstr tot

L25  ANSWER 1 OF 19  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:        2005:451253  HCAPLUS
DOCUMENT NUMBER:         142:487543
TITLE:                   Compositions, kits, and methods for the
                         treatment of conditions associated with elevated
                         cholesterol levels using HMG CoA synthase and
                         reductase and soluble fibers
INVENTOR(S):             Moreyra, Abel Ennio; Koraym, Ashraft M.; Wilson, Alan
                         Chaney; Carryl, Owen Rickford
PATENT ASSIGNEE(S):      The Procter & Gamble Company, USA; University of
                         Medicine and Dentistry of New Jersey
SOURCE:                  PCT Int. Appl., 19 pp.
                         CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005046796 | A2 | 20050526 | WO 2004-US37427 | 20041108 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-518183P P 20031107

AB Disclosed herein are methods of treating a condition associated with elevated cholesterol levels are provided, comprising administering to a mammal in need of such treatment a safe and effective amount of a cholesterol biosynthesis inhibitor and a soluble fiber. Further disclosed herein are kits comprising a first **composition** comprising a cholesterol biosynthesis inhibitor selected from the group consisting of **HMG CoA reductase inhibitors**, HMG CoA synthase inhibitors, and mixts. thereof; and a second **composition** comprising a soluble fiber. Even further described are **compns.** comprising a cholesterol biosynthesis inhibitor selected from the group consisting of **HMG CoA reductase inhibitors**, HMG CoA synthase inhibitors, and mixts. thereof; and a soluble fiber. For example, the combination of simvastatin tablet and psyllium fiber powder had a good effect of lowering cholesterol level in males.

L25 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:92513 HCAPLUS
DOCUMENT NUMBER: 142:183433
TITLE: Stabilization of therapeutic agents using a carbonate salt of an amino acid in the presence of a saccharide and pharmaceutical **compositions**
INVENTOR(S): Lulla, Amar; Malhotra, Geena
PATENT ASSIGNEE(S): Cipla Limited, India
SOURCE: Brit. UK Pat. Appl., 35 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| GB 2404336 | A1 | 20050202 | GB 2003-17877 | 20030730 |
| WO 2005011737 | A2 | 20050210 | WO 2004-GB3305 | 20040730 |
| WO 2005011737 | A3 | 20050421 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-17877 A 20030730

AB Therapeutic agents, which are degrade when present in a pharmaceutical formulation, may be stabilized by admixing a stabilizing agent comprising at least one carbonate salt of an amino acid, wherein, at least in the case where the therapeutic agent is a **HMG-CoA reductase inhibitor**, or an ACE inhibitor, the stabilizing agent is enhanced by further comprising one or more saccharides. The therapeutic agent susceptible to degradation may be selected from **HMG-CoA reductase inhibitors**, ACE inhibitors, antihistaminics, benzimidazoles and anti-viral agents, (including nucleoside reverse transcriptase inhibitors). The carbonate salt of the amino acid is preferably present as either the group I or II alkali or alkali earth metal salt thereof, and the amino acid is preferably selected from the group consisting of glycine, arginine and lysine. The saccharide is preferably selected from the group consisting of lactose, sucrose, glucose, mannitol, xylitol, maltitol, sorbitol and erythritol, either in anhydrous or hydrated form. Such combinations may be combined with a pharmaceutically acceptable carrier or excipient to provide a pharmaceutical formulation. Tablets were prepared from a dry mix containing quinapril-HCl, monosodium glycine carbonate, lactose and Crosspovidone. Binder solution, lubricants, and coatings were also used.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:58227 HCAPLUS
DOCUMENT NUMBER: 142:156266
TITLE: Novel compounds and **compositions** comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and their use in treating or preventing cardiovascular disease and other disorders
INVENTOR(S): Kutney, James P.; Pritchard, Haydn P.; Lukic, Tatjana
PATENT ASSIGNEE(S): Forbes Medi-Tech Inc., Can.
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005005453 | A2 | 20050120 | WO 2004-CA999 | 20040709 |
| WO 2005005453 | A3 | 20050609 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2003-615456 A 20030709
OTHER SOURCE(S): MARPAT 142:156266
GI



AB The present invention provides, in one aspect, novel compds. comprising sterols and/or stanols and a cholesterol biosynthesis inhibitors, having the following formulas R2(CH2)nCO2R, R2R, R2COCO2R, I-III [R = sterol, stanol; R2 = cholesterol biosynthesis inhibitor with at least one free and reactive carboxyl group; R3 = cholesterol biosynthesis inhibitor with at least one free and reactive hydroxyl group; R4 = derived from ascorbic acid; X = H, biol. acceptable metal, alkaline earth metal; n = 1-5], including salts, solvates and prodrugs of thereof in treating or preventing cardiovascular disease and other disorders. In another aspect, the present invention provides **compns.** comprising at least one sterol and/or stanol ester and at least one cholesterol biosynthesis inhibitor. Also provided are methods of treating or preventing a variety of diseases, conditions and disorders by administering the compds. or **compns.** provided herein.

L25 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:995960 HCAPLUS
DOCUMENT NUMBER: 141:416027
TITLE: Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a **HMG CoA reductase inhibitor**
INVENTOR(S): Urata, Yasuo; Hoshino, Shoji; Kawamura, Hitoshi; Okamoto, Hiroshi; Furukawa, Noboru
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004098583 | A1 | 20041118 | WO 2004-US13633 | 20040430 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 2005020668 | A1 | 20050127 | US 2004-835916 | 20040430 |
| PRIORITY APPLN. INFO.: | | | US 2003-467418P | P 20030502 |
| | | | US 2003-471495P | P 20030516 |
| | | | US 2003-477372P | P 20030610 |
| | | | US 2004-534856P | P 20040108 |

AB The invention provides a combination comprising (a) S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate (I) or prodrug of the active form thereof, and (b) at least one **HMG CoA reductase inhibitor.** Also provided are a pharmaceutical **composition**, package, and a kit comprising the the active ingredients, as well as a method for treatment and prophylaxis of a cardiovascular disorder involving the use of the the active ingredients. Thus, the combination of I and a **HMG CoA reductase inhibitor** decreased the atherogenic index in rabbits on a high cholesterol diet.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2004:965104 HCAPLUS |
| DOCUMENT NUMBER: | 141:384361 |
| TITLE: | Sugar intake-ability enhancer |
| INVENTOR(S): | Shimomura, Iichiro; Takagi, Toshiyuki |
| PATENT ASSIGNEE(S): | Sankyo Company, Limited, Japan |
| SOURCE: | PCT Int. Appl., 29 pp.<br>CODEN: PIXXD2 |
| DOCUMENT TYPE: | Patent |
| LANGUAGE: | Japanese |
| FAMILY ACC. NUM. COUNT: | 1 |

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004096276 | A1 | 20041111 | WO 2004-JP6093 | 20040427 |
| WO 2004096276 | C2 | 20050331 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | JP 2003-123781 | A | 20030428 |
| | JP 2004-12257 | A | 20040120 |

AB It is intended to provide a medicinal **composition** containing an **HMG-CoA reductase inhibitor** as the active ingredient which aims at: enhancing the ability to intake sugar into warm-blooded animal cells; treating diabetes; treating or preventing diabetic complications; treating or preventing diabetes or diabetic complications caused by insulin resistance syndrome, and so on. For example, tablets containing pravastatin Na were formulated.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:60308 HCAPLUS
DOCUMENT NUMBER: 140:99668
TITLE: Medicinal **composition** for mitigating blood lipid or lowering blood homocysteine containing **HMG-CoA reductase inhibitors** and pyridoxine compounds
INVENTOR(S): Kondo, Tatsuhito; Takagi, Ikuo; Nakayama, Masato; Torizumi, Yasuhiro
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004006919 | A1 | 20040122 | WO 2003-JP8674 | 20030708 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2492781 | AA | 20040122 | CA 2003-2492781 | 20030708 |
| JP 2004189716 | A2 | 20040708 | JP 2003-272681 | 20030710 |

PRIORITY APPLN. INFO.:
JP 2002-202121 A 20020711
JP 2002-343586 A 20021127
WO 2003-JP8674 W 20030708

AB Disclosed is a safe drug for mitigating blood lipid and for reducing the amount of blood homocysteine. It is a medicinal **composition** containing an **HMG-CoA reductase inhibitor** and a pyridoxine compound The effect of simvastatin in combination with pyridoxine hydrochloride on blood cholesterol in beagle dog was examined A tablet containing simvastatin 1.67, pyridoxine hydrochloride 16.7, and other ingredients q.s. to 200 mg was prepared
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:913007 HCAPLUS
DOCUMENT NUMBER: 139:386419
TITLE: Combination of an **HMG-CoA reductase inhibitor** and a nitrate ester
INVENTOR(S): Scaramuzzino, Giovanni
PATENT ASSIGNEE(S): Italy
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003094923 | A1 | 20031120 | WO 2003-EP4860 | 20030508 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1505986 | A1 | 20050216 | EP 2003-735372 | 20030508 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |

PRIORITY APPLN. INFO.: IT 2002-MI1012 A 20020513
WO 2003-EP4860 W 20030508

OTHER SOURCE(S): MARPAT 139:386419

AB The present invention relates to the therapeutic combination of an **HMG-CoA reductase inhibitor** (statin) and a nitrate ester and is useful mainly for the preparation of medicaments for the prevention and treatment of coronary diseases as myocardial infarction and cerebrovascular diseases as stroke. Particularly, as a nitrate ester, a nitrate prodrug of aspirin, salicylic acid or vitamin E is used. The **compns.**, compared to single components, have the advantages to be without toxic effects, mainly due to statins, and to be more effective. The effect of combination of simvastatin and 2-acetyloxy-benzoic acid 3-nitroxymethylphenyl ester on blood chemical in rats was examined

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:717761 HCAPLUS
DOCUMENT NUMBER: 139:235434
TITLE: **Compositions** containing insulin-secretion stimulant and a **HMG-CoA reductase inhibitor** for reducing blood glucose and cholesterol
INVENTOR(S): Freese, Lori M.; Gorham, Thomas R.; Wheeler-Davis, Jennifer A.
PATENT ASSIGNEE(S): Upsher-Smith Laboratories, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003171407 | A1 | 20030911 | US 2002-94004 | 20020307 |
| WO 2003075933 | A1 | 20030918 | WO 2003-US6937 | 20030306 |
| W: CA | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR | | | | |

PRIORITY APPLN. INFO.: US 2002-94004 A 20020307

AB The invention provides a pharmaceutical **composition** which is a combination of an insulin-secretion stimulant and a **HMG-CoA reductase inhibitor.** Suitable insulin-secretion stimulants include the sulfonylurea drugs, and suitable **HMG-CoA reductase inhibitors** include the statin drugs. The **composition** may be formulated to provide extended-release characteristics of 1 or both of the active components. Also provided are methods for treating a diabetic patient by using a combination of an insulin-secretion stimulant and a **HMG-CoA reductase inhibitor.** Practice of the methods of the invention may result in the administration of fewer dosages to the patient. The invention also provides a pharmaceutical **composition** which is a combination of an antihyperglycemic drug, particularly a biguanide compound, in combination with a **HMG-CoA reductase inhibitor.** Also provided are methods for treating a diabetic patient using a combination of an antihyperglycemic biguanide compound and a **HMG-CoA reductase inhibitor.**

L25 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:455033 HCAPLUS
DOCUMENT NUMBER: 139:41802
TITLE: Stabilized pharmaceuticals containing **HMG-CoA reductase inhibitors**
INVENTOR(S): Pflaum, Zlatko; Kerc, Janez
PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia
SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U. S. Ser. No. 591,322.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003109584 | A1 | 20030612 | US 2002-298187 | 20021115 |
| US 6806290 | B2 | 20041019 | | |
| US 6531507 | B1 | 20030311 | US 2000-591322 | 20000609 |
| ES 2215050 | T3 | 20041001 | ES 2000-931486 | 20000609 |
| PRIORITY APPLN. INFO.: | | | US 2000-591322 A2 | 20000609 |
| | | | EP 2000-931486 A | 20000609 |

AB Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivs. and analogs thereof are known as **HMG-CoA reductase inhibitors** and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a **HMG-CoA reductase inhibitor** which is stabilized by forming a homogeneous

**composition** with a buffering substance or a basifying substance. This homogeneous **composition** is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. **Pravastatin Sodium** (5 g) with chromatog. purity 99.5% and pH 7.4 (1%)/7.7 (5%) was dissolved in MeOH (30 mL), and Na2CO3 (10 mg, dissolved in 0.15 mL of water) was added and finally, EtOAc (400 mL containing 2% of water) was added. Fter 1 h the resulted crystals were filtered off, washed with fresh EtOAc (50 mL) and dried at 40° for 6 h in vacuo. The chromatog. purity of resulting crystals (4.3 g) was 99.6%.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:368876 HCAPLUS
DOCUMENT NUMBER: 138:374167
TITLE: **HMG-CoA reductase inhibitor compositions** with content uniformity, and storage-stable solid preparations packed with zeolite
INVENTOR(S): Iwata, Yukiya; Ochiai, Naoya
PATENT ASSIGNEE(S): Taiyo Pharmaceutical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 2003137778 | A2 | 20030514 | JP 2001-335390 | 20011031 |

PRIORITY APPLN. INFO.: JP 2001-335390 20011031
OTHER SOURCE(S): MARPAT 138:374167
AB Title **compns.** contain [HOCHR2CH2CH(OH)CH2CO2-]m (R1)m+ (R1 = H, alkali metal, alkaline earth metal; R2 = organic residue; m = 1, 2) and low-substituted hydroxypropyl cellulose (I), and the content uniformity is <25% according to the test of Japanese Pharmacopeia 14th edition. Also claimed are solid prepns. containing the **HMG-CoA reductase inhibitors** and packed with zeolites. Thus, tablets containing pravastatin Na and I showed content uniformity 14.8%, vs. 29.88%, when carmellose Ca was used instead of I.

L25 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:196949 HCAPLUS
DOCUMENT NUMBER: 138:226745
TITLE: **HMG-CoA reductase inhibitors** stabilized by a buffer or basifying substance
INVENTOR(S): Pflaum, Zlatko; Kerc, Janez
PATENT ASSIGNEE(S): LEK Pharmaceuticals D.D., Slovenia
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| US 6531507 | B1 | 20030311 | US 2000-591322 | 20000609 |
| AU 2000049434 | A5 | 20011217 | AU 2000-49434 | 20000609 |
| ES 2215050 | T3 | 20041001 | ES 2000-931486 | 20000609 |
| US 2003109584 | A1 | 20030612 | US 2002-298187 | 20021115 |
| US 6806290 | B2 | 20041019 | | |
| PRIORITY APPLN. INFO.: | | | EP 2000-931486 A | 20000609 |
| | | | US 2000-591322 A | 20000609 |
| | | | WO 2000-IB773 A | 20000609 |

AB The present invention relates to a **HMG-CoA reductase inhibitor** which is stabilized by forming a homogeneous **composition** with a buffering substance or a basifying substance. This homogeneous **composition** is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia. Pravastatin Na is stabilized by addition of Na2CO3.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:868726 HCAPLUS
DOCUMENT NUMBER: 137:358160
TITLE: Pharmaceutical **composition** comprising a **HMG-CoA reductase inhibitor**
INVENTOR(S): Hedge, Deepak; Kulkarni, Sushrut
PATENT ASSIGNEE(S): Biochemie Gesellschaft m.b.H., Austria
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002089788 | A2 | 20021114 | WO 2002-EP4891 | 20020503 |
| WO 2002089788 | A3 | 20021212 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| EP 1392277 | A2 | 20040303 | EP 2002-735331 | 20020503 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 2004167085 | A1 | 20040826 | US 2004-476816 | 20040413 |
| US 6911472 | B2 | 20050628 | | |
| PRIORITY APPLN. INFO.: | | | GB 2001-11077 A | 20010504 |
| | | | WO 2002-EP4891 W | 20020503 |

AB A pharmaceutical **composition** comprising an **HMG-CoA reductase inhibitor**, i.e., a statin, as an active ingredient, and an aminosugar, as a pH adjusting (basifying) agent, is described. **Compns.** comprising dehydroepiandrosterone (DHEA), a desquamating agent selected from retinoids, acylated salicylic acid derivs. or **HMG-CoA reductase**

**inhibitors**, and sugar derivs., and comprising germs for a koji-making raw material and monacolin K, are excluded. For example, tablets were obtained containing **pravastatin sodium** 10.00%, lactose (filler) 68.20%, microcryst. cellulose (filler) 13.50%, polyvinylpyrrolidone (binder) 0.50%, croscarmellose sodium (disintegrant) 6.00%, Mg stearate (lubricant) 1.00%, and Meglumine (pH adjusting agent) 0.80%. Tablets were stable for > 1 mo under normal environment humidity conditions.

L25 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:504607 HCAPLUS
DOCUMENT NUMBER: 137:93594
TITLE: Preparation of cyclobutene derivatives as agents for use in combination with **HMG-CoA reductase inhibitors**
INVENTOR(S): Kohama, Takafumi; Inaba, Toshimori; Kurata, Hitoshi
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 674 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002051396 | A1 | 20020704 | WO 2001-JP11294 | 20011221 |
| W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| JP 2002255799 | A2 | 20020911 | JP 2001-391028 | 20011225 |
| PRIORITY APPLN. INFO.: | | | JP 2000-395948 A | 20001226 |

OTHER SOURCE(S): MARPAT 137:93594
GI




AB The title compds. I [R1 is cycloalkyl, aryl, etc.; R2 is cycloalkyl, aryl, heterocyclic ring, etc.; R3 and R4 are each hydrogen or the like; A is a group of the general formula Q1 (wherein R5 is hydrogen or the like; R6 is an amine residue or the like; X and Y are each oxygen or the like; and Z is a single bond or the like); G is alkylene or the like; and when the dotted line is a double bond, D is carbon atom and E is :NO, when the dotted line is a single bond, D is CH or the like and E is NH or the like] are prepared A pharmaceutical **composition** containing **HMG-CoA reductase inhibitor** and I is claimed. In hamsters fed feed containing 0.3% cholesterol and 10% coconut oil, the

administration of pravastatin at 0.01% (weight/weight) alone caused 26% increase in high d. lipoprotein cholesterol; the combined administration of pravastatin and a cyclobutene derivative of this invention at 0.01% (weight/weight) caused 41% increase in high d. lipoprotein cholesterol. A formulation containing **pravastatin sodium** and a compound of this invention is given.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:171683 HCAPLUS
DOCUMENT NUMBER: 136:205466
TITLE: Medicinal **compositions** containing **HMG-CoA reductase inhibitors** and angiotensin II receptor antagonists for preventing or treating heart failure
INVENTOR(S): Lee, Tsung Ming; Lee, Bai-Ching; Su, Shen-Fang; Hsiao, Chia-Ling; Chu, Chia-Wei
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002017913 | A1 | 20020307 | WO 2001-JP7437 | 20010829 |
| W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, ZA | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| AU 2001084413 | A5 | 20020313 | AU 2001-84413 | 20010829 |
| JP 2002145770 | A2 | 20020522 | JP 2001-259399 | 20010829 |
| CA 2420844 | AA | 20030228 | CA 2001-2420844 | 20010829 |
| EP 1314425 | A1 | 20030528 | EP 2001-963398 | 20010829 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR | | | | |
| US 2003181500 | A1 | 20030925 | US 2003-374171 | 20030226 |
| US 2005059720 | A1 | 20050317 | US 2004-977645 | 20041029 |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| JP 2000-260949 | A | 20000830 |
| WO 2001-JP7437 | W | 20010829 |
| US 2003-374171 | A3 | 20030226 |

AB Disclosed are medicinal **compns.** comprising an **HMG-CoA reductase inhibitor** selected from the group consisting of pravastatin, simvastatin, lovastatin, pitavastatin and ZD-4522, and an angiotensin II receptor antagonist optionally together with a calcium channel blocker. The preventive effect of administration of pravastatin 10, losartan 50, and amlodipine 5 mg/day for 6 mo on left ventricle hypertrophy in patients was examined

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:903840 HCAPLUS
DOCUMENT NUMBER: 136:25125

TITLE: Stabilized pharmaceutical **compositions** of statin derivs. as **HMG-CoA reductase inhibitors**
INVENTOR(S): Pflaum, Zlatko; Kere, Janez
PATENT ASSIGNEE(S): Lek Pharmaceutical and Chemical Company D.D., Slovenia
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001093860 | A1 | 20011213 | WO 2000-IB773 | 20000609 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2412326 | AA | 20011213 | CA 2000-2412326 | 20000609 |
| AU 2000049434 | A5 | 20011217 | AU 2000-49434 | 20000609 |
| EP 1292293 | A1 | 20030319 | EP 2000-931486 | 20000609 |
| EP 1292293 | B1 | 20040225 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| JP 2004501121 | T2 | 20040115 | JP 2002-501433 | 20000609 |
| AT 260101 | E | 20040315 | AT 2000-931486 | 20000609 |
| ES 2215050 | T3 | 20041001 | ES 2000-931486 | 20000609 |
| RU 2246943 | C2 | 20050227 | RU 2002-134764 | 20000609 |
| NO 2002005784 | A | 20021202 | NO 2002-5784 | 20021202 |
| BG 107360 | A | 20031128 | BG 2002-107360 | 20021206 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| EP 2000-931486 | A | 20000609 |
| US 2000-591322 | A | 20000609 |
| WO 2000-IB773 | W | 20000609 |

AB Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivs. and analogs thereof are known as **HMG-CoA reductase inhibitors** and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a **HMG-CoA reductase inhibitor** which is stabilized by forming a homogeneous **composition** with a buffering substance or a basifying substance. This homogeneous **composition** is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and

hyperlipidemia. Pravastatin Na is stabilized by addition of Na carbonate.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:677395 HCAPLUS
DOCUMENT NUMBER: 133:256826
TITLE: Coating agents for oral formulations containing **HMG-CoA reductase inhibitors**
INVENTOR(S): Usui, Fusao; Yada, Shuichi; Kawabata, Kiyoshi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 2000264846 | A2 | 20000926 | JP 1999-70089 | 19990316 |
| PRIORITY APPLN. INFO.: | | | JP 1999-70089 | 19990316 |

AB Oral prepns. containing **HMG-CoA reductase inhibitors**, basic compds., and water-soluble polymers, are coated with a **composition** containing hydroxypropyl Me cellulose acetate succinate and plasticizers, preferably tri-Et citrate. This invention coated preparation allows maintaining of drug blood concentration and prevents isomerization of the drug, e.g. pravastatin. Tablets were formulated containing pravastatin Na, lactose, Crospovidone, Mg aluminate metasilicate, hydroxypropyl cellulose, and Mg stearate. The tablets were coated with a solution containing hydroxypropyl Me cellulose acetate succinate 12.5, tri-Et citrate 2.5, and 70% ethanolic aqueous solution 85 parts.

L25 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:98321 HCAPLUS
DOCUMENT NUMBER: 128:196661
TITLE: Antithrombotic and antiatherogenic pharmaceutical **composition** including a thienopyridine derivative and an **HMG-CoA reductase inhibitor**
INVENTOR(S): Daste, Georges; Herbert, Jean-Marc
PATENT ASSIGNEE(S): Sanofi, Fr.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9804259 | A1 | 19980205 | WO 1997-FR1353 | 19970721 |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,

| | | | | | |
|---|---|---|---|---|---|
| | GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| FR | 2751540 | A1 | 19980130 | FR 1996-9474 | 19960726 |
| FR | 2751540 | B1 | 19981016 | | |
| ZA | 9706247 | A | 19990115 | ZA 1997-6247 | 19970715 |
| CA | 2261099 | AA | 19980205 | CA 1997-2261099 | 19970721 |
| CA | 2261099 | C | 20030415 | | |
| AU | 9738526 | A1 | 19980220 | AU 1997-38526 | 19970721 |
| AU | 725949 | B2 | 20001026 | | |
| EP | 914124 | A1 | 19990512 | EP 1997-935593 | 19970721 |
| EP | 914124 | B1 | 20040121 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | |
| BR | 9710560 | A | 19990817 | BR 1997-10560 | 19970721 |
| CN | 1228698 | A | 19990915 | CN 1997-197539 | 19970721 |
| CN | 1109547 | B | 20030528 | | |
| JP | 2000500781 | T2 | 20000125 | JP 1998-508545 | 19970721 |
| JP | 3553610 | B2 | 20040811 | | |
| NZ | 333826 | A | 20000929 | NZ 1997-333826 | 19970721 |
| RU | 2176504 | C2 | 20011210 | RU 1999-103623 | 19970721 |
| EE | 3853 | B1 | 20021015 | EE 1999-28 | 19970721 |
| AT | 258052 | E | 20040215 | AT 1997-935593 | 19970721 |
| PT | 914124 | T | 20040531 | PT 1997-935593 | 19970721 |
| ES | 2214632 | T3 | 20040916 | ES 1997-935593 | 19970721 |
| CZ | 294664 | B6 | 20050216 | CZ 1999-176 | 19970721 |
| PL | 188739 | B1 | 20050429 | PL 1997-331339 | 19970721 |
| KR | 2000029484 | A | 20000525 | KR 1999-700501 | 19990122 |
| US | 6218403 | B1 | 20010417 | US 1999-230299 | 19990122 |
| NO | 9900321 | A | 19990322 | NO 1999-321 | 19990125 |
| HK | 1019405 | A1 | 20031017 | HK 1999-104578 | 19991101 |
| PRIORITY APPLN. INFO.: | | | | FR 1996-9474 A | 19960726 |
| | | | | WO 1997-FR1353 W | 19970721 |

OTHER SOURCE(S): MARPAT 128:196661
GI




I

AB A pharmaceutical **composition** containing (a) a thienopyridine derivative (I; R = H, C1-4 alkoxycarbonyl) or a pharmaceutically acceptable salt thereof; and (b) an **HMG-CoA-reductase inhibitor**, is disclosed. A combination of 5 mg/kg clopidogrel and 5 mg/kg simavastatin had synergistic effect and inhibited the formation of thrombose by 72% in rabbits. A 2-layered pharmaceutical tablet contained ticlopidine hydrochloride 200.00, microcryst. cellulose 69.88, maize starch 31.20, polyvidone 6.24, citric acid 3.12, stearic acid 0.78, magnesium stearate 0.78 mg in the first layer and simavastatin 20.00, butydroyxanisole 0.04, ascorbic acid 5.00, citric acid 2.50, microcryst. cellulose 10.00, maize starch 20.00, lactose 141.50, magnesium stearate

1.00, methylhydroy Pr cellulose 1.65, hydroxypropyl cellulose 1.65, titanium dioxide 1.50, talc 0.60, yellow ferric oxide 0.092, and red ferric oxide 0.023 mg in the second layer.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:192587 HCAPLUS
DOCUMENT NUMBER: 126:258927
TITLE: Effects of low-dose **pravastatin sodium** on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year
AUTHOR(S): Harsch, Michael; Braesen, Jan Hinrich; Niendorf, Axel
CORPORATE SOURCE: Institute Pathology, University Hamburg, Hamburg, 20246, Germany
SOURCE: Atherosclerosis (Shannon, Ireland) (1997), 128(2), 139-147
CODEN: ATHSBL; ISSN: 0021-9150
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The aim of this study was to evaluate the cholesterol-lowering and antiatherosclerotic effect of the **HMG-CoA reductase inhibitor pravastatin sodium** at a dosage comparable to human therapy. Twelve heterozygous WHHL rabbits (13 mo old) were fed 100 g per day of a low cholesterol (0.03%) enriched diet for 12 mo. Six of these animals also received **pravastatin sodium** at a daily dose of 1 mg/kg body weight (verum group). In the verum group, total plasma cholesterol levels were lower by 47% ($P < 0.05$) and relative aortic plaque volume (% ratio of total plaque volume to the aortic lumen) was reduced by 78% ($P < 0.05$), when compared to the control group. Plaque **composition** was analyzed at 30 cross-sectional levels of the entire aortic wall using a grid window. Compared to the control group, the plaque type, in terms of architecture and **composition**, was altered as follows: lesions in the verum group had no confluent atheromatous cores and showed a pattern of a diffuse mixture of the main plaque components with a decreased relative content of necrosis (-44%) and an increased relative content of smooth muscle cells (+19%), whereas the relative content of macrophage-derived foam cells and collagen were nearly unaffected. Furthermore, a similar plaque volume and type was observed in animals with comparable cholesterol profiles. There was no histol. evidence for structurally damaging effects of **pravastatin sodium** on the arterial wall. We conclude that **pravastatin sodium** reduces total plasma cholesterol levels in this animal model, thereby leading to smaller plaques and a different plaque type.

L25 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:178769 HCAPLUS
DOCUMENT NUMBER: 126:176899
TITLE: Synergistic combination comprising an insulin sensitizer and a **HMG-CoA reductase inhibitor** for treating arteriosclerosis
INVENTOR(S): Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 753298 | A1 | 19970115 | EP 1996-304924 | 19960703 |
| EP 753298 | B1 | 20011121 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| CA 2180296 | AA | 19970104 | CA 1996-2180296 | 19960702 |
| NO 9602784 | A | 19970106 | NO 1996-2784 | 19960702 |
| AU 9656261 | A1 | 19970116 | AU 1996-56261 | 19960702 |
| AU 706628 | B2 | 19990617 | | |
| JP 09071540 | A2 | 19970318 | JP 1996-172137 | 19960702 |
| JP 3651816 | B2 | 20050525 | | |
| US 5798375 | A | 19980825 | US 1996-676090 | 19960702 |
| IL 118778 | A1 | 19990714 | IL 1996-118778 | 19960702 |
| RU 2158607 | C2 | 20001110 | RU 1996-112769 | 19960702 |
| TW 474809 | B | 20020201 | TW 1996-85107984 | 19960702 |
| ZA 9605650 | A | 19970127 | ZA 1996-5650 | 19960703 |
| CN 1148492 | A | 19970430 | CN 1996-112170 | 19960703 |
| CN 1089584 | B | 20020828 | | |
| CZ 286832 | B6 | 20000712 | CZ 1996-1982 | 19960703 |
| AT 209046 | E | 20011215 | AT 1996-304924 | 19960703 |
| ES 2165474 | T3 | 20020316 | ES 1996-304924 | 19960703 |
| PT 753298 | T | 20020328 | PT 1996-304924 | 19960703 |
| US 6159997 | A | 20001212 | US 1998-61446 | 19980416 |
| HK 1011928 | A1 | 20020628 | HK 1998-113080 | 19981210 |
| JP 2004075691 | A2 | 20040311 | JP 2003-359698 | 20031020 |
| JP 2004250455 | A2 | 20040909 | JP 2004-96229 | 20040329 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| JP 1995-167291 | A | 19950703 |
| JP 1996-172137 | A3 | 19960702 |
| US 1996-676090 | A3 | 19960702 |

AB A combination of 1 or more HMG-CoAreductase inhibitors (e.g., pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with 1 or more insulin sensitizers (e.g., troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy] ethoxy)benzyl}thiazolidine-2,4-dione) exhibits a synergistic effect and is better at prevention and/or treatment of arteriosclerosis and/or xanthoma than is either of the components of the combination alone. Thus, **pravastatin sodium** 0.5, troglitazone 20, Crospovidone 1.5, and Na lauryl sulfate 0.2 g were blended and the mixture was divided among 100 capsules, each containing 5 mg **pravastatin sodium** and 200 mg troglitazone. The preparation of some thiazolidine-2,4-diones is reported.

=> d 127 ibib abs hitstr tot

L27 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:98321 HCAPLUS
DOCUMENT NUMBER: 128:196661
TITLE: Antithrombotic and antiatherogenic pharmaceutical **composition** including a thienopyridine derivative and an **HMG-CoA reductase inhibitor**
INVENTOR(S): Daste, Georges; Herbert, Jean-Marc

PATENT ASSIGNEE(S): Sanofi, Fr.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|---|---|---|---|---|---|
| WO 9804259 | A1 | 19980205 | WO 1997-FR1353 | 19970721 | <-- |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | | |
| FR 2751540 | A1 | 19980130 | FR 1996-9474 | 19960726 | <-- |
| FR 2751540 | B1 | 19981016 | | | |
| ZA 9706247 | A | 19990115 | ZA 1997-6247 | 19970715 | |
| CA 2261099 | AA | 19980205 | CA 1997-2261099 | 19970721 | <-- |
| CA 2261099 | C | 20030415 | | | |
| AU 9738526 | A1 | 19980220 | AU 1997-38526 | 19970721 | <-- |
| AU 725949 | B2 | 20001026 | | | |
| EP 914124 | A1 | 19990512 | EP 1997-935593 | 19970721 | |
| EP 914124 | B1 | 20040121 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | | |
| BR 9710560 | A | 19990817 | BR 1997-10560 | 19970721 | |
| CN 1228698 | A | 19990915 | CN 1997-197539 | 19970721 | |
| CN 1109547 | B | 20030528 | | | |
| JP 2000500781 | T2 | 20000125 | JP 1998-508545 | 19970721 | |
| JP 3553610 | B2 | 20040811 | | | |
| NZ 333826 | A | 20000929 | NZ 1997-333826 | 19970721 | |
| RU 2176504 | C2 | 20011210 | RU 1999-103623 | 19970721 | |
| EE 3853 | B1 | 20021015 | EE 1999-28 | 19970721 | |
| AT 258052 | E | 20040215 | AT 1997-935593 | 19970721 | |
| PT 914124 | T | 20040531 | PT 1997-935593 | 19970721 | |
| ES 2214632 | T3 | 20040916 | ES 1997-935593 | 19970721 | |
| CZ 294664 | B6 | 20050216 | CZ 1999-176 | 19970721 | |
| PL 188739 | B1 | 20050429 | PL 1997-331339 | 19970721 | |
| KR 2000029484 | A | 20000525 | KR 1999-700501 | 19990122 | |
| US 6218403 | B1 | 20010417 | US 1999-230299 | 19990122 | |
| NO 9900321 | A | 19990322 | NO 1999-321 | 19990125 | |
| HK 1019405 | A1 | 20031017 | HK 1999-104578 | 19991101 | |

PRIORITY APPLN. INFO.: FR 1996-9474 A 19960726
WO 1997-FR1353 W 19970721

OTHER SOURCE(S): MARPAT 128:196661
GI



I

AB A pharmaceutical **composition** containing (a) a thienopyridine derivative (I; R = H, C1-4 alkoxycarbonyl) or a pharmaceutically acceptable salt thereof; and (b) an **HMG-CoA-reductase inhibitor**, is disclosed. A combination of 5 mg/kg clopidogrel and 5 mg/kg simavastatin had synergistic effect and inhibited the formation of thrombose by 72% in rabbits. A 2-layered pharmaceutical tablet contained ticlopidine hydrochloride 200.00, microcryst. cellulose 69.88, maize starch 31.20, polyvidone 6.24, citric acid 3.12, stearic acid 0.78, magnesium stearate 0.78 mg in the first layer and simavastatin 20.00, butydroyxanisole 0.04, ascorbic acid 5.00, citric acid 2.50, microcryst. cellulose 10.00, maize starch 20.00, lactose 141.50, magnesium stearate 1.00, methylhydroy Pr cellulose 1.65, hydroxypropyl cellulose 1.65, titanium dioxide 1.50, talc 0.60, yellow ferric oxide 0.092, and red ferric oxide 0.023 mg in the second layer.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:192587 HCAPLUS
DOCUMENT NUMBER: 126:258927
TITLE: Effects of low-dose **pravastatin sodium** on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year
AUTHOR(S): Harsch, Michaël; Braesen, Jan Hinrich; Niendorf, Axel
CORPORATE SOURCE: Institute Pathology, University Hamburg, Hamburg, 20246, Germany
SOURCE: Atherosclerosis (Shannon, Ireland) (**1997**), 128(2), 139-147
CODEN: ATHSBL; ISSN: 0021-9150
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The aim of this study was to evaluate the cholesterol-lowering and antiatherosclerotic effect of the **HMG-CoA reductase inhibitor pravastatin sodium** at a dosage comparable to human therapy. Twelve heterozygous WHHL rabbits (13 mo old) were fed 100 g per day of a low cholesterol (0.03%) enriched diet for 12 mo. Six of these animals also received **pravastatin sodium** at a daily dose of 1 mg/kg body weight (verum group). In the verum group, total plasma cholesterol levels were lower by 47% ($P < 0.05$) and relative aortic plaque volume (% ratio of total plaque volume to the aortic lumen) was reduced by 78% ($P < 0.05$), when compared to the control group. Plaque **composition** was analyzed at 30 cross-sectional levels of the entire aortic wall using a grid window. Compared to the control group, the plaque type, in terms of architecture and **composition**, was altered as follows: lesions in the verum group had no confluent atheromatous cores and showed a pattern of a diffuse mixture of the main

plaque components with a decreased relative content of necrosis (-44%) and an increased relative content of smooth muscle cells (+19%), whereas the relative content of macrophage-derived foam cells and collagen were nearly unaffected. Furthermore, a similar plaque volume and type was observed in animals with comparable cholesterol profiles. There was no histol. evidence for structurally damaging effects of **pravastatin sodium** on the arterial wall. We conclude that **pravastatin sodium** reduces total plasma cholesterol levels in this animal model, thereby leading to smaller plaques and a different plaque type.

L27 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:178769 HCAPLUS
DOCUMENT NUMBER: 126:176899
TITLE: Synergistic combination comprising an insulin sensitizer and a **HMG-CoA reductase inhibitor** for treating arteriosclerosis
INVENTOR(S): Tsujita, Yoshio; Horikoshi, Hiroyoshi; Shiomi, Masashi; Ito, Takashi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 753298 | A1 | 19970115 | EP 1996-304924 | 19960703 <-- |
| EP 753298 | B1 | 20011121 | | |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| CA 2180296 | AA | 19970104 | CA 1996-2180296 | 19960702 <-- |
| NO 9602784 | A | 19970106 | NO 1996-2784 | 19960702 <-- |
| AU 9656261 | A1 | 19970116 | AU 1996-56261 | 19960702 <-- |
| AU 706628 | B2 | 19990617 | | |
| JP 09071540 | A2 | 19970318 | JP 1996-172137 | 19960702 <-- |
| JP 3651816 | B2 | 20050525 | | |
| US 5798375 | A | 19980825 | US 1996-676090 | 19960702 <-- |
| IL 118778 | A1 | 19990714 | IL 1996-118778 | 19960702 |
| RU 2158607 | C2 | 20001110 | RU 1996-112769 | 19960702 |
| TW 474809 | B | 20020201 | TW 1996-85107984 | 19960702 |
| ZA 9605650 | A | 19970127 | ZA 1996-5650 | 19960703 <-- |
| CN 1148492 | A | 19970430 | CN 1996-112170 | 19960703 <-- |
| CN 1089584 | B | 20020828 | | |
| CZ 286832 | B6 | 20000712 | CZ 1996-1982 | 19960703 |
| AT 209046 | E | 20011215 | AT 1996-304924 | 19960703 |
| ES 2165474 | T3 | 20020316 | ES 1996-304924 | 19960703 |
| PT 753298 | T | 20020328 | PT 1996-304924 | 19960703 |
| US 6159997 | A | 20001212 | US 1998-61446 | 19980416 |
| HK 1011928 | A1 | 20020628 | HK 1998-113080 | 19981210 |
| JP 2004075691 | A2 | 20040311 | JP 2003-359698 | 20031020 |
| JP 2004250455 | A2 | 20040909 | JP 2004-96229 | 20040329 |
| PRIORITY APPLN. INFO.: | | | JP 1995-167291 A | 19950703 |
| | | | JP 1996-172137 A3 | 19960702 |
| | | | US 1996-676090 A3 | 19960702 |

AB A combination of 1 or more HMG-CoAreductase inhibitors (e.g., pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with 1

or more insulin sensitizers (e.g., troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy] ethoxy)benzyl}thiazolidine-2,4-dione) exhibits a synergistic effect and is better at prevention and/or treatment of arteriosclerosis and/or xanthoma than is either of the components of the combination alone. Thus, **pravastatin sodium** 0.5, troglitazone 20, Crospovidone 1.5, and Na lauryl sulfate 0.2 g were blended and the mixture was divided among 100 capsules, each containing 5 mg **pravastatin sodium** and 200 mg troglitazone. The preparation of some thiazolidine-2,4-diones is reported.

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 299.92 | 653.93 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -43.80 | -43.80 |

STN INTERNATIONAL LOGOFF AT 12:05:03 ON 09 AUG 2005